Document:

<PAGE>   1
                                                              EXHIBIT 10(iii)(a)

                                                              June 28, 2000

Mr. James A. Miller
757 Baldwin Road
Highland Park, Illinois  60035

Dear Jim:

         This is to confirm the agreement which we have reached regarding your
service as Chairman of the Board of Directors and of the Executive Committee of
General Binding Corporation (the Company).

         1. The term of your service commenced on June 9, 2000 and will continue
until the earlier of (a) your death or disability, or (b) termination of your
service by written notice given either by you at any time or by the Board at
least one hundred eighty (180) days (or such shorter period to which you and the
Company may agree) prior to the effective date of such termination.

         2. As Chairman, you will have general responsibility along with the
President and CEO of the Company for developing the overall corporate strategy
of the Company. You will also serve on such other Committees of the Board to
which you may be appointed. You agree to devote such time as you determine to be
necessary for the proper conduct of such duties.

         3. As your compensation for serving as Chairman of the Board and the
Executive Committee, and on any other Committees of the Board, you will receive
an annual retainer of $300,000, payable monthly in advance and commencing June
9, 2000 at the rate of $25,000. As an additional inducement for you to accept
the role of Chairman, you have been granted an option to purchase 75,000 shares
of common stock of the Company. The exercise price for the shares will be $7.813
per share, which reflects the closing price of the common stock on June 12,
2000, which was the date of grant. The option vested and became exercisable as
to 6,250 shares as of June 12, 2000, and will vest and become exercisable as to
an additional 6,250 shares on the 12th of each of the following 11 months,
provided that all of the option shares shall vest and become exercisable

<PAGE>   2

Mr. James A. Miller
757 Baldwin Road
Highland Park, Illinois  60035
June 28, 2000

Page 2

upon the termination of your service pursuant to clause (a) of Paragraph 1
above, or upon termination of your service by the Board giving notice pursuant
to clause (b) of Paragraph 1 above, or in the event of a change in control of
the Company. In the event you give notice of termination pursuant to clause (b)
of Paragraph 1 above, any portion of the option which has not vested and become
exercisable by the effective date of termination shall be forfeited. In the
event of a change in control, you will be grossed-up for any excise taxes (and
for all taxes on the gross-up payment) which may be imposed as a result of the
compensation described in this Paragraph 3. Upon becoming vested and
exercisable, the option will remain exercisable through June 11, 2010,
notwithstanding the termination of your service as Chairman hereunder or as a
director of the Company. The option shall be evidenced by a separate option
agreement, substantially in the form attached hereto. The Company agrees to
promptly file a Registration Statement with the Securities and Exchange
Commission relating to the 75,000 option shares.

         4. Since you are a director and not an employee of the Company, you
acknowledge and agree that you are not entitled to participate in any other
compensation and employee benefit plans, programs and practices of the Company,
including (but not by way of limitation) annual or long-term incentive
compensation plans, retirement plans and severance pay plans. You shall not
receive any additional compensation for serving as a director of the Company.

         5. During the term of your service, you will be entitled to be
reimbursed, pursuant to the Company's applicable expense reimbursement policies
(which, for this purpose, shall include first class air travel), for travel and
other expenses incurred by you in connection with your services rendered
pursuant to this letter agreement, including the cost of commuting between
Florida and Illinois to conduct Company business. You will also be provided
office and secretarial support consistent with the position of Chairman.

         6. To the fullest extent permitted by law, the Company will, during and
after the term of your service as Chairman, indemnify you (including the
advancement of expenses) for any judgments, fines, amounts paid in settlement
and reasonable expenses, including attorneys' fees, incurred by you in
connection with the defense of any lawsuit or other claim to which you are made
or threatened to be made a party by reason of being or having been an officer,
director or employee of the Company.

<PAGE>   3

Mr. James A. Miller
757 Baldwin Road
Highland Park, Illinois  60035
June 28, 2000

Page 3

         7. Since you are not an employee, the Company will not provide for the
withholding of any taxes with respect to any payment in cash, shares of stock
and/or other property made by or on behalf of the Company to you.

         If the foregoing is consistent with your understanding, please
countersign the enclosed copy of this letter and return it to me. On behalf of
the GBC Board of Directors, shareholders, and employees, thank you for
undertaking this important position at the Company. We all look forward to
working with you.

                                          Sincerely,

                                          GENERAL BINDING CORPORATION

                                          By: /s/ Govi C. Reddy
                                             --------------------------------
                                          Govi C. Reddy,
                                          President and Chief Executive Officer

Accepted and agreed to
this 28 day of June, 2000

/s/  James A. Miller
-----------------------------
      James A. Miller

<PAGE>   4
                           GENERAL BINDING CORPORATION

                             STOCK OPTION AGREEMENT

TO:           James A. Miller

OPTION DATE:  June 12, 2000

OPTION PRICE: $7.813

         As an inducement to you to accept the position of Chairman of the Board
and Chairman of the Executive Committee of General Binding Corporation ("GBC"),
you are hereby granted an Option by GBC, effective as of the date hereof, to
purchase 75,000 shares of GBC Common Stock at a price per share of $7.813,
subject to the terms and conditions set forth herein.

         This Option may be exercised as to 6,250 shares on or after the date
hereof, and as to an additional 6,250 shares on or after July 12, 2000 and the
12th day of each month thereafter through and including May 12, 2001, provided
your service as Chairman continues through such dates. Notwithstanding the
foregoing, the exercise dates shall accelerate and the Option shall be fully
exercisable upon your death or disability, in the event you cease to be Chairman
due to notice from GBC pursuant to our separate Letter Agreement, or upon the
occurrence of a Change in Control as defined on Attachment I hereto. In the
event you cease to be Chairman due to notice from you pursuant to such Letter
Agreement, any portion of the Option which has not become exercisable as of the
effective date of such termination shall be forfeited and shall not thereafter
become exercisable. No part of this Option is transferable or assignable in
whole or in part by you during your lifetime.

         The manner in which you may exercise this Option is by giving written
notice to the Vice President, Secretary and General Counsel of GBC accompanied
by either (1) a check in payment of the Option Price for the number of shares of
the Option being exercised, or (2) tendering a sufficient number of
previously-owned shares of GBC Common Stock with a fair market value equal
(subject to adjustment for fractional shares) to the cost of the Option being
exercised.

         To the extent this Option becomes exercisable, it may be exercised in
whole or in part at any time prior to June 12, 2010, at which date the Option
shall expire and no longer be exercisable.

         No amendment, modification, or waiver of this Option in whole or in
part shall be binding unless consented to in writing by either the Chairman of
the Compensation Committee or the

<PAGE>   5

President of GBC, and by you, and no amendment may cause you to be unfavorably
affected with respect to the Option granted hereunder.

         No shares shall be issued, transferred or delivered upon exercise of
this Option unless the Board is satisfied that there has been full compliance
with all applicable requirements of the Securities Act of 1933. GBC shall
promptly file a Registration Statement on Form S-8 with the Securities and
Exchange Commission to register the shares subject to this Option.

         The Board of Directors of GBC will make or provide for such adjustment
in the exercise price and/or in the number or kinds of shares of GBC covered by
this Option or reserved for issuance by GBC as it may deem to be equitable as a
result of any change in the number or kind of outstanding shares of GBC
resulting from any reorganization, recapitalization, stock split, stock
dividend, merger, consolidation, rights offering or other change in capital
structure or like transaction.

         Please acknowledge your acceptance of this Option by signing the copy
of this Option agreement and return it to me.

                                       GENERAL BINDING CORPORATION

                                       By: /s/ Govi C. Reddy
                                          ------------------------------------
                                          Govi C. Reddy,
                                          President and Chief Executive Officer

                                          /s/ James A. Miller
                                          -------------------------------------
                                          James A. Miller

<PAGE>   6

                                         Attachment 1 to Stock Option Agreement

                               Certain Definitions

         A.    "Change in Control" shall mean the first to occur of:

               (a) Any person (as defined in Section 13(d) and 14(d) of the
               Securities Exchange Act of 1934, as amended (the Exchange Act)),
               excluding for this purpose, (i) any person who, as of June 28,
               2000, was the beneficial owner of 10% or more of the combined
               voting power of the voting securities of General Binding
               Corporation (the Company), or (ii) the Company or any subsidiary
               of the Company, or (iii) any employee benefit plan of the Company
               or any subsidiary of the Company, or any person or entity
               organized, appointed or established by the Company for or
               pursuant to the terms of any such plan which acquires beneficial
               ownership of voting securities of the Company, is or becomes the
               beneficial owner (as defined in Rule 13d-3 under the Exchange
               Act), directly or indirectly of securities of the Company
               representing more than 50% or more of the combined voting power
               of the Company's then outstanding securities; provided, however,
               that no Change in Control will be deemed to have occurred as a
               result of a change in ownership percentage resulting solely from
               an acquisition of securities by the Company; and provided further
               that no Change in Control will be deemed to have occurred if a
               person inadvertently acquires an ownership interest of more than
               50% but then promptly reduces that ownership interest below 50%;

               (2)     During any two consecutive years (not including any
               period prior to June 28, 2000), individuals who at the beginning
               of such two-year period constitute the Board of Directors of the
               Company and any new director (except for a director designated by
               a person who has entered into an agreement with the Company to
               effect a transaction described elsewhere in this definition of
               Change in Control) whose election by the Board or nomination for
               election by the Company's stockholders was approved by a vote of
               at least two-thirds of the directors then still in office who
               either were directors at the beginning of the period or whose
               election or nomination for election was previously so approved
               (such individuals and any such new director, the Incumbent Board)
               cease for any reason to constitute at least a majority of the
               Board; or

                                      A-1

<PAGE>   7

               (3)     Consummation of a reorganization, merger or
               consolidation or sale or other disposition of all or
               substantially all of the assets of the Company (a Business
               Combination), in each case, unless, following such Business
               Combination, (i) all or substantially all of the individuals and
               entities who were the beneficial owners of outstanding voting
               securities of the Company immediately prior to such Business
               Combination beneficially own, directly or indirectly, more than
               50% of the combined voting power of the then outstanding voting
               securities entitled to vote generally in the election of
               directors, as the case may be, of the Company resulting from such
               Business Combination (including, without limitation, a Company
               which as a result of such transaction owns the Company or all or
               substantially all of the Company's assets either directly or
               through one or more subsidiaries) in substantially the same
               proportions as their ownership, immediately prior to such
               Business Combination of the outstanding voting securities of the
               Company; or

               (4)     Approval by the stockholders of the Company of a complete
               liquidation or dissolution of the Company.

                                      A-2<PAGE>   1
                                                                   EXHIBIT 10.1

                          REDACTED FOR CONFIDENTIALITY

                           JOINT DEVELOPMENT AGREEMENT

                                       FOR

                              PROCESS TECHNOLOGIES

                                      AMONG

                            LUCENT TECHNOLOGIES INC.,

                  LUCENT TECHNOLOGIES MICROELECTRONICS PTE LTD.

                                       AND

                   CHARTERED SEMICONDUCTOR MANUFACTURING LTD.

                   EFFECTIVE AS OF THE 31ST DAY OF JULY, 2000

                          CHARTERED-LUCENT CONFIDENTIAL

<PAGE>   2
<TABLE>
<CAPTION>
                                               CONTENTS

SECTION                                                                                         PAGE
-------                                                                                         ----
<S>                                                                                             <C>
1.0   DEFINITIONS                                                                                  1
2.0   OBJECTIVES OF THE PROJECT                                                                    3
3.0   DEVELOPMENT PROGRAM                                                                          4
4.0   STEERING COMMITTEE AND EXECUTIVE COMMITTEE                                                   5
5.0   PROJECT UNDERTAKINGS                                                                         6
6.0   PROJECT FUNDING                                                                             15
7.0   SINGAPORE BELL LABORATORIES                                                                 16
8.0   300mm FAB                                                                                   17
9.0   BACKGROUND INTELLECTUAL PROPERTY -- RIGHTS AND LICENSES                                     17
10.0  INTELLECTUAL PROPERTY OWNERSHIP                                                             18
11.0  CONFIDENTIALITY                                                                             22
12.0  LIMITATION OF LIABILITY                                                                     23
13.0  COMPLIANCE WITH RULES AND REGULATIONS AND INDEMNIFICATION                                   24
14.0  TERM AND TERMINATION                                                                        25
15.0  PUBLICITY AND TRADEMARKS AND TRADENAMES                                                     27
16.0  NON-ASSIGNABILITY                                                                           27
17.0  NOTICES                                                                                     27
18.0  AGREEMENT PREVAILS                                                                          29
19.0  NOTHING CONSTRUED                                                                           30
20.0  FORCE MAJEURE                                                                               30
21.0  CHOICE OF LAW                                                                               30
22.0  HEADINGS                                                                                    30
23.0  WAIVER                                                                                      31
24.0  RELEASES VOID                                                                               31
25.0  POWER TO SIGN                                                                               31
26.0  SURVIVAL OF OBLIGATIONS                                                                     31
27.0  EXPORT CONTROL                                                                              31
28.0  DISPUTE RESOLUTION                                                                          32
29.0  PARTIAL INVALIDITY                                                                          33
30.0  COUNTERPARTS                                                                                33
31.0  RELATIONSHIP OF PARTIES                                                                     33
32.0  INTEGRATION                                                                                 33
ATTACHMENT A: DEVELOPMENT PLANS                                                                   35
ATTACHMENT B: TOTAL PROJECT COST                                                                  44
ATTACHMENT C: SINGAPORE BELL LABORATORIES STAFF                                                   45
ATTACHMENT D: INFORMATION FOR RELEASE TO THIRD PARTIES                                            46
ATTACHMENT E: COMPLETION OF PROJECT FOR 0.12um, 0.10um AND 0.08um PROCESSES                       48
ATTACHMENT F: PROCEDURE FOR JOINT SELECTION OF TOOL SET AND MATERIALS
              FOR JOINT DEVELOPMENT OF THE PROCESSES                                              49
</TABLE>

                         CHARTERED-LUCENT CONFIDENTIAL

<PAGE>   3
                           JOINT DEVELOPMENT AGREEMENT
                            FOR PROCESS TECHNOLOGIES

THIS JOINT DEVELOPMENT AGREEMENT is made and entered into effective the 31st day
of July 2000 by and among LUCENT TECHNOLOGIES INC., having its principal place
of business at 600 Mountain Avenue, Murray Hill, NJ 07974, U.S.A., acting
through its Microelectronics Group, LUCENT TECHNOLOGIES MICROELECTRONICS PTE
LTD., having a place of business at 3 Kallang Sector, Kolam Ayer Industrial
Park, Singapore 349278 (hereinafter collectively referred to as "Lucent") and
CHARTERED SEMICONDUCTOR MANUFACTURING LTD., having its principal place of
business at 60 Woodlands Industrial Park D Street 2, Singapore 738406
(hereinafter referred to as "Chartered").

                               W I T N E S S E T H

WHEREAS, Lucent and Chartered wish to cooperate for the purpose of developing
three generations of advanced CMOS logic process technologies with foundry
competitive cost, feature and schedule attributes that will enable the Parties
to achieve a market leading position in semiconductor processing capability.

NOW, THEREFORE, the Parties agree as follows:

1.0  DEFINITIONS

     1.1  "Background Information" shall mean certain informative material and
technical information, including any mask work or copyright rights in any of the
foregoing, relating to the manufacture of CMOS semiconductor devices which
(i) is owned or controlled by a Party, (ii) exists as of the Effective Date of
this Joint Development Agreement or which is developed by a Party hereto after
the Effective Date of this Joint Development Agreement but such development is
outside the scope of this Joint Development Agreement, and (iii) which is
disclosed by one Party to the other pursuant to the Development Program.

     1.2  "Bell Laboratories" shall mean Bell Laboratories, a division of
Lucent, headquartered in Murray Hill, New Jersey, or a similar laboratory
established by the Microelectronics Group of Lucent with Bell Laboratories
personnel in 2001. The Parties acknowledge that as a result of a public
announcement made by Lucent on July 20, 2000 that the Microelectronics Group of
Lucent will be spun off from Lucent at some point in 2001 and that, as a result
of such spin-off, Bell Laboratories will remain with Lucent. However, those
individuals within Bell Laboratories that support the Microelectronics Group
will become part of the new company.

                          CHARTERED-LUCENT CONFIDENTIAL

                                      - 1 -

<PAGE>   4
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of this document have been omitted and
                are filed separately with the Securities and Exchange Commission

     1.3   "Chartered's Background Information" shall mean Background
Information owned or controlled by Chartered and/or any of its Subsidiaries.

     1.4   "Chartered's Facility" shall mean Chartered's wafer processing
facilities, including joint ventures between Chartered and a third party.

     1.5   "Development Program" shall mean the activities relating to the
development of the Processes conducted pursuant to the respective Development
Plan, as defined in Section 3.1.

     1.6   "EDA" shall mean electronic design automation.

     1.7   "EDB" shall mean the Economic Development Board of Singapore.

     1.8   "Effective Date" shall mean the 31st day of July, 2000.

     1.9   "Enhancement Modules" shall mean collectively the *****************
******************************************* modules, and "Enhancement Module"
shall mean any one of them.

     1.10  "Foreground Information" shall mean informative material and
technical information, including any mask work rights or copyrights in any of
the foregoing, relating to the manufacture of CMOS semiconductor devices which
is created during the Development Program by employees, agents or consultants of
either Party engaged in the development of the Processes pursuant to such
Development Program.

     1.11  "Future Technologies" shall mean process technologies for the
manufacture of semiconductor devices that are developed by Chartered or by
Lucent either solely or jointly with others, after the conclusion or termination
of the applicable Development Program.

     1.12  "Joint Invention" shall mean an invention made by one or more
employees, agents or consultants of Chartered in conjunction with one or more
employees, agents or consultants of Lucent.

     1.13  "Licensed Products" shall mean any products, in wafer, die or
packaged form manufactured using (i) Processes developed during the applicable
Development Program, or (ii) Future Technologies developed after the applicable
Development Program.

     1.14  "Lucent's Background Information" shall mean Background Information
owned or controlled by Lucent and/or any of its Subsidiaries.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 2 -
<PAGE>   5
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of this document have been omitted and
                are filed separately with the Securities and Exchange Commission

     1.15  "Lucent's Facility" shall mean Lucent's wafer processing facilities
in Orlando, Florida or SMP in Singapore.

     1.16  "Party" shall mean Lucent or Chartered.

     1.17  "Process" shall mean any of the continuum of processes from
0.12um, 0.10um to 0.08um advanced deep sub-micron CMOS digital logic
and linear (mixed signal) technology, each of which shall include the following:
********************************************************************************
*******************, each as more specifically described in Attachment A, and
"Processes" shall mean all of them collectively.

     1.18  "Process Specifications" shall mean the specifications for the
Processes, as agreed in writing by the Steering Committee.

     1.19  "Project" shall mean the Chartered-Lucent joint project described in
Section 2.1.

     1.20  "RISC" shall mean Research Incentive Scheme for Companies.

     1.21  "Singapore Bell Laboratories" shall mean the Bell Laboratories
organization located or to be located in Singapore.

     1.22  "SMP" shall mean Silicon Manufacturing Partners Pte Ltd.

     1.23  "Subsidiary" of a company shall mean a corporation or other legal
entity (i) the majority (i.e., greater than 50%) of whose shares or other
securities entitled to vote for election of directors (or other managing
authority) is now or hereafter controlled by such company either directly or
indirectly; or (ii) which does not have outstanding shares or securities but the
majority of whose ownership interest representing the right to manage such
corporation or other legal entity is now or hereafter owned and controlled by
such company either directly or indirectly; but any such corporation or other
legal entity shall be deemed to be a Subsidiary of such company only as long as
such control or ownership and control exists.

2.0  OBJECTIVES OF THE PROJECT

     2.1  The objectives of this Project are to:

          2.1.1  develop and deliver to manufacturing a continuum of foundry
competitive Processes, namely 0.12um, 0.10um and 0.08um, ("the 0.12um Project",
"the 0.10um Project" or "the

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 3 -
<PAGE>   6
0.08um Project", respectively);

          2.1.2  establish Singapore Bell Laboratories in Singapore for
semiconductor process, materials and integrated circuit development, utilizing a
substantial number of Singaporean and Singapore Permanent Resident engineers;

          2.1.3  work together with EDA providers under a separate agreement
mutually agreed upon by the Parties to develop process libraries for Lucent and
Chartered customers on 0.12um through 0.08um Processes;

          2.1.4  train highly qualified engineers in advanced wafer process
technologies with substantial emphasis on Singaporean and Singapore Permanent
Resident engineers; and

          2.1.5  (if market and economic conditions permit) capitalize
and staff a 300mm development laboratory in Singapore.

3.0  DEVELOPMENT PROGRAM

     3.1  Chartered and Lucent shall cooperatively conduct the Development
Program for the development of each of the Processes in accordance with a plan
and budget relating to that respective Process (the "Development Plan") prepared
by the Steering Committee. The Development Plan with respect to each Process
shall establish: (i) the scope of the Process development which will be
performed; (ii) the objectives, work plan activities and time schedules with
respect to the Development Program; (iii) the respective obligations of the
Parties with respect to the Development Program; and (iv) the Process
Specifications. The initial Development Plan for each Process is set forth in
Attachment A.

     3.2  The initial Development Plan with respect to 0.12um, 0.10um
and 0.08um CMOS logic technologies shall be attached hereto as
Attachments A-1, A-2 and A-3, respectively. The Steering Committee shall review
the Development Plan on an on-going basis and may propose changes to the
Development Plan then in effect per the procedures outlined in Section 4.0. In
order to expedite the development, Chartered may, on terms mutually agreed
between Chartered and Lucent, locate certain engineers at Lucent's Facility in
Orlando to commence development activities prior to the approval of the formal
Development Plan by the Executive Committee.

     3.3  Chartered and Lucent shall each use commercially reasonable efforts
to conduct the Development Program in accordance with the Development Plan and
within the time schedules contemplated therein.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 4 -

<PAGE>   7
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of  this document have been omitted and
                are filed separately with the Securities and Exchange Commission

     3.4  During the term of this Joint Development Agreement and for a
period of ******* **** thereafter, each Party shall furnish to the other Party,
without any compensation, technical information relating to corrections,
improvements and modifications to be made by such Party to each of the qualified
Process, provided however, that a Party shall not be required to furnish to the
other Party such technical information, if it is prohibited or restricted from
doing so pursuant to any contractual agreement entered into by such Party prior
to execution of this Joint Development Agreement or is prohibited from doing so
under U.S. or Singapore export law. Nothing contained in this Section 3.4 shall
be construed as conferring by implication, estoppel or otherwise any license or
right under any patent, whether or not the use of any corrections, improvements
or modifications necessarily requires the use of any patent having enforceable
rights at any time anywhere in the world.

4.0  STEERING COMMITTEE AND EXECUTIVE COMMITTEE

     4.1  Chartered and Lucent shall establish a committee (the "Steering
Committee") to oversee, review and recommend the direction of the Development
Program. The responsibilities of the Steering Committee shall include:
(i) monitoring and overseeing the progress of the Development Program and
ensuring open and frequent exchanges between the Parties; (ii) preparing the
initial Development Plan and revisions thereof for approval; (iii) preparing
annual Project budgets and quarterly forecasts of Project expenditure; (iv)
coordinating all invention disclosure activities resulting from the Development
Program; (v) maintaining the Development Program schedule, design rules and
electrical parameter specifications, (vi) proposing changes to the Development
Program schedule, design rules and electrical parameter specifications; and
(vii) appoint one representative from each company to review and approve
publications arising from the joint Development Program.

     4.2  The Steering Committee shall consist of three (3) representatives
from each of the Parties. Each Party may replace its Steering Committee
representatives at any time, with written notice to the other Party. The
Steering Committee shall meet according to a schedule to be mutually agreed upon
and the quorum for each Steering Committee meeting shall be four (4)
representatives.

     4.3  Neither Party may alter the scope, direction or schedule of the
Development Program without the Steering Committee's review and the Executive
Committee's approval.

     4.4  Chartered and Lucent shall establish a committee (the "Executive
Committee") to oversee and review the direction of the Project. The
responsibilities of the Executive Committee shall include: (i) approval of the
Development Plan and proposed revisions thereof; (ii) approval of the selection
of tools and materials for development; (iii) resolution of differences
identified by the Steering Committee; (iv) review of the Project to ensure
foundry competitive Processes; (v) review and approval of the annual Project
budget, quarterly forecast of Project expenditure and budget overruns.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 5 -
<PAGE>   8

     4.5  The Executive Committee shall consist of two (2) representatives
from each of the Parties. Each Party may replace its Executive Committee
representatives at any time, with written notice to the other Party. The
Executive Committee shall meet according to a schedule to be mutually agreed
upon and the quorum for each Executive Committee meeting shall be three (3)
representatives.

     4.6  Decisions of the Steering Committee and Executive Committee shall
be unanimous. In the event that the Executive Committee is unable to agree on
any issue, such issue shall be submitted to a committee (the "Management
Committee") consisting of one (1) senior manager from each Party, being in the
case of Chartered, the President and CEO and being in the case of Lucent, the IC
President in the Lucent Technologies Microelectronics Group. Matters that are
submitted to the Management Committee shall be resolved within fourteen (14)
days of submission (or such other date as mutually agreed by the Management
Committee), failing which the issue shall be resolved in accordance with
Section 28 (Dispute Resolution).

5.0  PROJECT UNDERTAKINGS

     5.1  0.12um Process Development And Transfer Project

          5.1.1  The initial 0.12um Development Plan (which shall
include the list of deliverables, headcount, resources and timeline) is defined
in Attachment A-1-1.

          5.1.2  Chartered shall undertake the following:

                 (a)  to jointly develop, integrate (including integration
                      of the developed Process to the manufacturing tool set)
                      and demonstrate manufacturability of the 0.12um
                      Process;

                 (b)  in the event that additional tools for
                      development (beyond those purchased by Lucent as at
                      the Effective Date) are required, to jointly select
                      such additional tools for development which will
                      maximize efficiency in manufacturing and minimize
                      cost of ownership. Furthermore, such additional tools
                      will be selected such that a majority of the tools
                      selected for the development of the 0.12um Process
                      is reusable for the development of the 0.10um
                      Process. The procedure for joint selection of tools
                      for development is defined in Attachment F. The
                      Executive Committee will approve the final selection
                      of tools for development. Irrespective of whether the
                      manufacturing tool set is identical to the tool set
                      for development, Chartered shall provide engineering
                      resources for the transfer of the resulting 0.12um
                      Process to one of Chartered's Facility or SMP and
                      ensure successful qualification of such Process

                       CHARTERED-LUCENT CONFIDENTIAL

                                     - 6 -
<PAGE>   9
                 in such facility as defined in Attachment E;

                 (c)  to jointly provide design rules, electrical parameters and
                      other technical documents;

                 (d)  to jointly work with EDA providers, including Lucent,
                      under a separate agreement mutually agreed upon by the
                      Parties to develop design libraries, which include but are
                      not limited to standard cells, I/Os and ROM and RAM
                      compilers, for the 0.12um Process;

                 (e)  to jointly provide a process qualification plan (including
                      procedures) and qualification and reliability data for
                      representative products;

                 (f)  to jointly provide simulation and extraction models for
                      transistors and passive elements required to support
                      product designs;

                 (g)  to jointly conduct management project reviews;

                 (h)  to cooperate with Lucent to design a qualification device
                      for use in development, characterization and qualification
                      of the 0.12um Process;

                 (i)  to contract for the design of the qualification device and
                      reticles, and identify suitable product test vehicles for
                      use in development, characterization and qualification of
                      the 0.12um Process;

                 (j)  to provide program management and coordination for
                      Chartered assignees; and

                 (k)  to lead in the interface with EDB.

          5.1.3  Lucent shall undertake the following:

                 (a)  to jointly develop, integrate (including integration of
                      the developed Process to the manufacturing tool set) and
                      demonstrate manufacturability of the 0.12um Process;

                 (b)  in the event that additional tools for development (beyond
                      those purchased by Lucent as at the Effective Date) are
                      required, to jointly select such additional tools for
                      development which will maximize efficiency in
                      manufacturing and minimize cost of ownership. Furthermore,
                      such additional

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 7 -

<PAGE>   10
                      tools will be selected such that a majority of the tools
                      selected for the development of the 0.12um Process is
                      reusable for the development of the 0.10um Process. The
                      procedure for joint selection of tools for development is
                      defined in Attachment F. The Executive Committee will
                      approve the final selection of tools for development.
                      Irrespective of whether the manufacturing tool set is
                      identical to the tool set for development, Lucent shall
                      provide engineering resources for the transfer of the
                      resulting 0.12um Process to one of Chartered's Facility
                      or SMP and ensure successful qualification of such Process
                      in such facility as defined in Attachment E;

                 (c)  to jointly provide design rules, electrical parameters and
                      other technical documents;

                 (d)  to jointly work with EDA providers under a separate
                      agreement mutually agreed upon by the Parties to develop
                      design libraries, which include but are not limited to
                      standard cells, I/Os and ROM and RAM compilers, for the
                      0.12um Process;

                 (e)  to jointly provide a process qualification plan (including
                      procedures) and qualification and reliability data for
                      representative products;

                 (f)  to jointly provide simulation and extraction models for
                      transistors and passive elements required to support
                      product designs;

                 (g)  to jointly conduct management project reviews;

                 (h)  to design a qualification device for use in development,
                      characterization and qualification of the 0.12um
                      Process;

                 (i)  to provide design support and GDSII data for the
                      qualification device and assist Chartered in the
                      development, characterization and qualification of the
                      product test vehicles for the 0.12um Process;

                 (j)  to process wafers for the 0.12um Project per the
                      Workplan;

                 (k)  to provide a 0.12um development laboratory in Orlando,
                      Florida for the development, integration and demonstration
                      of manufacturability of the 0.12um Process;

                 (l)  to develop special modules like new materials, memory
                      cells and

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 8 -

<PAGE>   11
                      processes associated with advanced lithography tools; and

                 (m)  to provide manufacturing support for process steps that
                      have been established.

     5.2  0.10um Process Development And Transfer Project

          5.2.1  The initial 0.10um Development Plan (which shall include the
list of deliverables, headcount, resources and timeline) is defined in
Attachment A-2-1.

          5.2.2  Chartered shall undertake the following:

                 (a)  to jointly develop, integrate (including integration of
                      the developed Process to the manufacturing tool set) and
                      demonstrate manufacturability of the 0.10um Process;

                 (b)  to jointly select tools for development which will
                      maximize efficiency in manufacturing and minimize cost of
                      ownership. Furthermore, tools will be selected such that a
                      majority of the tools selected for the development of the
                      0.10um Process should be reusable for the development
                      of the 0.08um Process. The procedure for joint
                      selection of tools for development is defined in
                      Attachment F. The Executive Committee will approve the
                      final selection of tools for development. Irrespective of
                      whether the manufacturing tool set is identical to the
                      tool set for development, Chartered shall provide
                      engineering resources for the transfer of the resulting
                      0.10um Process to one of Chartered's Facility or SMP
                      and ensure successful qualification of such Process in
                      such facility as defined in Attachment E;

                 (c)  to jointly provide design rules, electrical parameters and
                      other technical documents;

                 (d)  to jointly work with EDA providers, including Lucent,
                      under a separate agreement mutually agreed upon by the
                      Parties to develop design libraries, which include but are
                      not limited to standard cells, I/Os and ROM and RAM
                      compilers, for the 0.10um Process;

                 (e)  to jointly provide a process qualification plan (including
                      procedures) and qualification and reliability data for
                      representative products;

                 (f)  to jointly provide simulation and extraction models for
                      transistors and

                         CHARTERED-LUCENT CONFIDENTIAL

                                      - 9 -
<PAGE>   12
                      passive elements required to support product designs;

                 (g)  to jointly conduct management project reviews;

                 (h)  to cooperate with Lucent to design a qualification device
                      for use in development, characterization and qualification
                      of the 0.10um Process;

                 (i)  to contract for the design of the qualification device and
                      reticles, and identify suitable product test vehicles for
                      use in development, characterization and qualification of
                      the 0.10um Process;

                 (j)  to provide program management and coordination for
                      Chartered assignees;

                 (k)  to provide a 0.10um development laboratory in
                      Chartered's Facility in Singapore for the development,
                      integration and demonstration of manufacturability of the
                      0.10um Process; and

                 (l)  to lead in the interface with EDB.

          5.2.3  Lucent shall undertake the following:

                 (a)  to jointly develop, integrate (including integration of
                      the developed Process to the manufacturing tool set) and
                      demonstrate manufacturability of the 0.10um Process;

                 (b)  to jointly select tools for development which will
                      maximize efficiency in manufacturing and minimize cost of
                      ownership. Furthermore, tools will be selected such that a
                      majority of the tools selected for the development of the
                      0.10um Process should be reusable for the development
                      of the 0.08um Process. The procedure for joint
                      selection of tools for development is defined in
                      Attachment F. The Executive Committee will approve the
                      final selection of tools for development. Irrespective of
                      whether the manufacturing tool set is identical to the
                      tool set for development, Lucent shall provide engineering
                      resources for the transfer of the resulting 0.10um
                      Process to one of Chartered's Facility or SMP and ensure
                      successful qualification of such Process in such facility
                      as defined in Attachment E;

                 (c)  to jointly provide design rules, electrical parameters and
                      other technical documents;

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 10 -
<PAGE>   13
                 (d)  to jointly work with EDA providers under a separate
                      agreement mutually agreed upon by the Parties to
                      develop design libraries, which include but are not
                      limited to standard cells, I/Os and ROM and RAM
                      compilers, for the 0.10um Process;

                 (e)  to jointly provide a process qualification plan
                      (including procedures) and qualification and reliability
                      data for representative products;

                 (f)  to jointly provide simulation and extraction models for
                      transistors and passive elements required to support
                      product designs;

                 (g)  to jointly conduct management project reviews;

                 (h)  to design a qualification device for use in
                      development, characterization and qualification of the
                      0.10um Process;

                 (i)  to provide design support and GDSII data for the
                      qualification device and assist Chartered in the
                      development, characterization and qualification of the
                      0.10um Process;

                 (j)  to process wafers for the 0.10um Project per the
                      Workplan;

                 (k)  to provide a 0.10um development laboratory in
                      Orlando, Florida for the development, integration and
                      demonstration of manufacturability of the 0.10um
                      Process;

                 (l)  to develop special modules like new materials, memory
                      cells and processes associated with advanced lithography
                      tools; and

                 (m)  to provide manufacturing support for process steps that
                      have been established.

     5.3  0.08um Process Development And Transfer Project

          5.3.1  The initial 0.08um Development Plan (which shall
include the list of deliverables, headcount, resources and timeline) is defined
in Attachment A-3-1.

          5.3.2  Chartered shall undertake the following:

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 11 -
<PAGE>   14
                 (a)  to jointly develop, integrate (including integration of
                      the developed Process to the manufacturing tool set)
                      and demonstrate manufacturability of the 0.08um
                      Process;

                 (b)  to jointly select tools for development which will
                      maximize efficiency in manufacturing and minimize cost
                      of ownership. Furthermore, tools will be selected such
                      that a majority of the tools selected for the
                      development of the 0.08um Process should be reusable
                      for the development of the next generation process
                      technology. The procedure for joint selection of tools
                      for development is defined in Attachment F. The
                      Executive Committee will approve the final selection of
                      tools for development. Irrespective of whether the
                      manufacturing tool set is identical to the tool set for
                      development, Chartered shall provide engineering
                      resources for the transfer of the resulting 0.08um
                      Process to one of Lucent's Facility or SMP and ensure
                      successful qualification of such Process in such
                      facility as defined in Attachment E;

                 (c)  to jointly provide design rules, electrical parameters
                      and other technical documents;

                 (d)  to jointly work with EDA providers, including Lucent,
                      under a separate agreement mutually agreed upon by the
                      Parties to develop design libraries, which include but
                      are not limited to standard cells, I/Os and ROM and RAM
                      compilers, for the 0.08um Process;

                 (e)  to jointly provide a process qualification plan
                      (including procedures) and qualification and
                      reliability data for representative products;

                 (f)  to jointly provide simulation and extraction models for
                      transistors and passive elements required to support
                      product designs;

                 (g)  to jointly conduct management project reviews;

                 (h)  to cooperate with Lucent to design a qualification
                      device for use in development, characterization and
                      qualification of the 0.08um Process;

                 (i)  to contract for the design of the qualification device
                      and reticles, and identify suitable product test
                      vehicles for use in development, characterization and
                      qualification of the 0.08um Process;

                 (j)  to lead in the interface with EDB;

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 12 -
<PAGE>   15
                 (k)  to process wafers for the 0.08um Project per the
                      Workplan;

                 (l)  to provide a 0.08um development laboratory in
                      Chartered's Facility in Singapore for the development,
                      integration and demonstration of manufacturability of
                      the 0.08um Process;

                 (m)  to develop special modules like new materials, memory
                      cells and processes associated with advanced
                      lithography tools; and

                 (n)  to provide manufacturing support for process steps that
                      have been established.

          5.3.3  Lucent shall undertake the following:

                 (a)  to jointly develop, integrate (including integration of
                      the developed Process to the manufacturing tool set)
                      and demonstrate manufacturability of the 0.08um
                      Process;

                 (b)  to jointly select tools for development which will
                      maximize efficiency in manufacturing and minimize cost
                      of ownership. Furthermore, tools will be selected such
                      that a majority of the tools selected for the
                      development of the 0.08um Process should be reusable
                      for the development of the next generation process
                      technology. The procedure for joint selection of tools
                      for development is defined in Attachment F. The
                      Executive Committee will approve the final selection of
                      tools for development. Irrespective of whether the
                      manufacturing tool set is identical to the tool set for
                      development, Lucent shall provide engineering resources
                      for the transfer of the resulting 0.08um Process to
                      one of Lucent's Facility or SMP and ensure successful
                      qualification of such Process in such facility as
                      defined in Attachment E;

                 (c)  to jointly provide design rules, electrical parameters
                      and other technical documents;

                 (d)  to jointly work with EDA providers under a separate
                      agreement mutually agreed upon by the Parties to
                      develop design libraries, which include but are not
                      limited to standard cells, I/Os and ROM and RAM
                      compilers, for the 0.08um Process;

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 13 -

<PAGE>   16
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of  this document have been omitted and
                are filed separately with the Securities and Exchange Commission

                 (e)  to jointly provide a process qualification plan
                      (including procedures) and qualification and
                      reliability data for representative products;

                 (f)  to jointly provide simulation and extraction models for
                      transistors and passive elements required to support
                      product designs;

                 (g)  to jointly conduct management project reviews;

                 (h)  to design a qualification device for use in
                      development, characterization and qualification of the
                      0.08um Process;

                 (i)  to provide design support and GDSII data for the
                      qualification device and assist Chartered in the
                      development, characterization and qualification of the
                      0.08um Process;

                 (j)  to provide program management and coordination for Lucent
                      assignees;

                 (k)  to provide a 0.08um development laboratory in
                      Lucent's Facility in Orlando for the development,
                      integration and demonstration of manufacturability of
                      the 0.08um Process; and

                 (l)  to develop special modules like new materials, memory
                      cells and processes associated with advanced
                      lithography tools.

     5.4  The Parties acknowledge that certain obligations of the Parties
listed in Sections 5.1, 5.2 and 5.3 may change over time. The Steering Committee
shall at the appropriate time, review and propose the most suitable amendments
to these obligations for approval by the Executive Committee. It is the Parties
intent that a major portion of the activities relating to the development of the
0.08um Process will be conducted in Chartered's Facility in Singapore.

     5.5  The Parties acknowledge that the tool set to be used in the
development of each of the Processes may not be fully utilized during the
Project. It is the desire of the Parties to utilize such excess capacity for the
manufacture of wafers for sale to third parties, in order to defray the costs of
development. Accordingly, Chartered undertakes that from ***********, it will,
if necessary, use its commercially reasonable efforts to procure customer
loadings for a minimum of *** eight-inch wafers per week, for manufacture in
Lucent's Facility in Orlando utilizing the Processes.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 14 -
<PAGE>   17
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of  this document have been omitted and
                are filed separately with the Securities and Exchange Commission

     5.6  Enhancement Modules

          5.6.1  The Parties will mutually agree on the Enhancement
Modules that will be included in the joint development Project.

          5.6.2  The Parties undertake to jointly develop the Enhancement
Modules on the terms and conditions to be agreed.

6.0  PROJECT FUNDING

     6.1  The Parties expect some reimbursements from EDB covering a portion
of the qualifying costs of the Project (the "EDB RISC"). Each Party agrees to
comply with all terms and conditions specified by EDB in connection with the EDB
RISC, and both Parties will cooperate to resolve any issues that are raised by
the EDB concerning the EDB RISC terms and conditions.

     6.2  Within one (1) month from the end of each calendar quarter,
Chartered and Lucent shall aggregate all agreed upon Project costs (excluding
the Equipment costs referred to in Section 6.6) that have been incurred by each
Party during the preceding calendar quarter (the "Aggregated Project Cost") for
submission, together with the relevant auditors' certification, by Chartered to
EDB for reimbursement under the EDB RISC.

     6.3  The objective of the cost sharing formula set out below is to
achieve **** sharing of the Aggregated Project Cost (after reimbursement under
the EDB RISC).

          (a)  The Party that has contributed more than *** of the Aggregated
               Project Cost ("Party A") shall be reimbursed in accordance with
               the following formula:

               **************************

               Where

               R(A)  =   Reimbursement for Party A for the relevant calendar
                         quarter
               PC(A) =   Party A's project cost for the relevant calendar
                         quarter
               APC   =   Aggregate Project Cost for the relevant calendar
                         quarter
               RISC  =   EDB RISC received for the relevant calendar quarter

          (b)  RISC shall first be paid to Party A to offset R(A). In the
               event that RISC is insufficient to offset R(A), then the
               Party that has contributed less than *** of the Aggregated
               Project Cost ("Party B") shall pay Party A the difference
               of R(A) and

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 15 -

<PAGE>   18

               RISC, such payment to be made as soon as reasonably
               practicable but in any event no later than thirty
               (30) days after the submission of the Aggregated
               Project Cost by Chartered to EDB for reimbursement
               under the EDB RISC. Chartered shall pay to Lucent
               such portion of the EDB RISC that is due to Lucent
               pursuant to this Section 6.3 as soon as reasonably
               practicable but in any event, no later than thirty
               30) days after Chartered's receipt of the EDB RISC
               from EDB.

          (c)  Any surplus RISC after offsetting R(A) shall be applied to
               Party B's share of the Project cost.

     6.4  The Total Project Cost is set out in Attachment B. Unless otherwise
set out in Attachment B, costs not identified in Attachment B shall be borne by
the Party incurring such cost, save that the Executive Committee may, on a
case-by-case basis and in accordance with Section 4.4, approve budget overruns
and the sharing of such costs between the Parties. The Parties acknowledge that
the costs set out in Attachment B may change over time due to changes in the
obligations of each Party and the activities to be performed in Singapore and
Orlando, as envisaged in Section 5.4. In such event, the Steering Committee will
propose the appropriate amendments to the Project budget for approval by the
Executive Committee.

     6.5  Chartered will act as the intermediary for submission of all claims
for qualifying costs to EDB. When making claims, the Parties shall ensure that
all receipts and statements are in form and substance acceptable to EDB, and the
Parties shall cooperate with EDB in securing any claims to which they are
entitled under the EDB RISC.

     6.6  The acquisition cost of all process equipment and related capital
items (the "Equipment") required to be purchased by each Party, in accordance
with the undertakings set out in Section 5, shall be borne solely by that Party
acquiring the Equipment.

     6.7  In the event that funding support from EDB ceases, neither this
Project nor this Joint Development Agreement shall terminate, but the Executive
Committee shall within thirty (30) days of notice of cessation of funding
support, meet to discuss alternative future funding arrangements.

7.0  SINGAPORE BELL LABORATORIES

     7.1  Lucent shall establish Singapore Bell Laboratories in accordance with
the terms hereunder.

     7.2  The Singapore Bell Laboratories staff shall have the qualifications
consistent with then prevailing Bell Laboratories staffing practices.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 16 -

<PAGE>   19

REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of  this document have been omitted and
                are filed separately with the Securities and Exchange Commission

     7.3  Singapore Bell Laboratories shall by ***************, include at least
forty (40) Bell Laboratories engineers, and forty (40) Chartered engineers that
are attached to Singapore Bell Laboratories. Furthermore, by ***************, at
least ************************ of the total Singapore Bell Laboratories
headcount (including attached personnel) shall consist of Singaporeans and
Singapore Permanent Residents.

     7.4  Lucent 's and Chartered's responsibilities for the Singapore Bell
Laboratories staff are set out in Attachment C.

     7.5  The Singapore Bell Laboratories staff will adhere to the
Development Program, and participate in the continuing Process development. It
is anticipated that the Singapore Bell Laboratories staff, will at appropriate
times, participate in academic exchanges with Singaporean universities, and
mentor Chartered's and SMP's junior engineers on terms to be mutually agreed.

8.0  300MM FAB

If market and economic conditions permit, Chartered and Lucent shall explore the
possibility of building or investing in a 300mm wafer development laboratory and
a 300mm wafer manufacturing facility in Singapore on terms and specifications
mutually agreeable to both Parties. The Parties agree that this intention does
not amount to any commitment by either Party to construct or invest in a 300mm
wafer manufacturing facility.

9.0  BACKGROUND INTELLECTUAL PROPERTY - RIGHTS AND LICENSES

     9.1  Chartered grants to Lucent a ****************************************
************************************* right to use Chartered's Background
Information, excluding patents (i) for performing those acts that are reasonably
necessary to enable Lucent to develop each of the Processes during the
respective Development Program and (ii) to make, have made, use, offer to sell,
sell or import Licensed Products during the Development Program relating to such
Process and after the conclusion or (subject to Section 14.2.5) termination of
the Development Program relating to such Process. The grant of the license in
this Section 9.1 includes the right, subject to the confidentiality provisions
set forth in this Joint Development Agreement, to (i) sublicense those portions
of Chartered's Background Information, excluding patents, that are necessarily
used when using the Foreground Information or Future Technologies to make, have
made, use, offer to sell, sell or import Licensed Products, and (ii) sublicense
Chartered's Background Information, excluding patents, to third parties, to
allow the third party to work with or for Lucent in the development of Future
Technologies.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 17 -

<PAGE>   20
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of  this document have been omitted and
                are filed separately with the Securities and Exchange Commission

     9.2  Lucent grants to Chartered a ****************************************
********************************** right to use Lucent's Background Information,
excluding patents (i) for performing those acts that are reasonably necessary to
enable Chartered to develop each of the Processes during the respective
Development Program and (ii) to make, have made, use, offer to sell, sell or
import Licensed Products during the Development Program relating to such Process
and after the conclusion or (subject to Section 14.2.5) termination of the
Development Program relating to such Process. The grant of the license in this
Section 9.2 includes the right, subject to the confidentiality provisions set
forth in this Joint Development Agreement, to (i) sublicense those portions of
Lucent's Background Information, excluding patents, that are necessarily used
when using the Foreground Information or Future Technologies to make, have made,
use, offer to sell, sell or import Licensed Products, and (ii) sublicense
Lucent's Background Information, excluding patents, to third parties, to allow
the third party to work with or for Chartered in the development of Future
Technologies.

     9.3  Subject to Section 10.2, there are no patent licenses being granted
in this Joint Development Agreement. The licensing of patents shall be governed
by the existing Patent License Agreement between Lucent and Chartered effective
as of January 1, 1998.

     9.4  The rights granted to Chartered shall include the right to disclose
to third party customers, subcontractors, EDA providers, and design service
providers of Chartered, technical information of the type specified in
Attachment D.

     9.5  The rights granted to Lucent shall include the right to disclose to
third party customers, subcontractors, EDA providers, and design service
providers of Lucent, technical information of the type specified in Attachment
D.

10.0  INTELLECTUAL PROPERTY OWNERSHIP

     10.1  All Foreground Information and any intellectual property rights
therein (other than patents) which are created: (i) solely by Lucent's
employees, agents or consultants or (ii) solely by Chartered's employees, agents
or consultants or (iii) by the employees, agents or consultants of both Lucent
and Chartered, shall be jointly owned by Lucent and Chartered with each Party
being free to use and/or license without accounting to the other. In addition,
in those jurisdictions where consent of all joint owners is required for
licensing, each joint owner agrees to provide such consent.

     10.2  The following provisions of this Section 10.2 shall apply only
with respect to any Joint Inventions. The term Invention shall be as defined by
Title 35 of the United States Code and shall include the intellectual property
rights which may be granted as a result of the filing of United States and
foreign patent applications, including provisional patent applications, and
further including without limitation, all reissues, extensions, substitutions,
continuations, continuations-in-part, and divisions of

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 18 -

<PAGE>   21

any of the foregoing.

          10.2.1  The Invention Disclosure Committee shall consist of one (1)
Chartered legal or technical representative, and one (1) Lucent legal or
technical representative. Either Party may replace its Invention Disclosure
Committee representatives at any time, with written notice to the other Party.
Each Party will maintain, compile and distribute the list of invention
disclosure submissions received within the last one (1) calendar month
determined by each Party as candidate Joint Inventions for consideration by the
Invention Disclosure Committee. Such list of Joint Inventions will be created
and shared by the Parties' respective Invention Disclosure Committee members
from Lucent and Chartered at least two (2) weeks in advance of the Invention
Disclosure Committee meeting date. The Invention Disclosure Committee will meet
(via telephone or face-to-face) every month to discuss and assign the Joint
Inventions. If there are less than two (2) submissions for a given calendar
month, the Invention Disclosure Committee meeting for that month shall be
postponed to the next Invention Disclosure Committee meeting date, and the
submission (if any) will be considered by the Invention Disclosure Committee at
the next Invention Disclosure Committee meeting date. If however there is one
invention disclosure, and no invention disclosure meetings are held for two (2)
successive months, an invention disclosure meeting will be held in the following
month to consider this submission. The Party that does not select this
submission will receive an additional submission in the next odd numbered
occurrence of submissions, as set forth in Clause 10.2.2 (a).

          10.2.2(a)  Joint Inventions in question shall be divided equally
between the Parties, with the Parties alternating their selection until all
submissions have been selected for assignment and ownership. If an odd number of
submissions are in question, then the Party which receives the lesser number of
inventions shall receive the greater number in the next odd numbered occurrence
of submissions whereas it is desirable that each Party receives half of the
total Joint Inventions created during the course of the Development Program.

          10.2.2(b)  The first Party to select a submission for assignment,
providing sole, individual ownership rights, and all rights and privileges
thereof, in all jurisdictions in the world attributed to it, shall be determined
by examining the last whole number (units column) in the Dow Jones Industrial
Average (DJIA) as reported in the Wall Street Journal on the first Tuesday of
the month in which the Invention Disclosure Committee meets to review the
submissions in question. If the last whole number is an even number (i.e.
0,2,4,6,8) then Lucent is the first Party to select, with each Party alternating
thereafter until all submissions have been selected for assignment. Similarly,
if the last whole number is an odd number (i.e. 1,3,5,7,9) then Chartered is the
first Party to select, with each Party alternating thereafter until all
submissions have been selected for assignment.

          10.2.2(c)  For example, on Tuesday May 2nd, 2000, the DJIA at the
time the market closed in New York was reported at 10,731.12 as reported in the
Wednesday May 3rd publication of the Wall Street Journal. Thus, in this example,
if the Invention Disclosure Committee was scheduled to

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 19 -
<PAGE>   22
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of  this document have been omitted and
                are filed separately with the Securities and Exchange Commission

meet in May 2000 to review the submissions received in the preceding month (for
this example, April 1, 2000 through April 30, 2000) then Chartered would be
provided first selection, thereafter alternating between Lucent and Chartered
until the list has been exhausted. Furthermore, the submissions in question for
assignment between the Parties would only be those submissions identified prior
to May 1, 2000.

          10.2.3  Lucent grants to Chartered under its assigned Joint
Inventions ********** ****************************** licenses for Licensed
Products in accordance with the license scope set forth in Section 10.2.5.
Chartered grants to Lucent under its assigned Joint Inventions,
**************************************************** licenses for Licensed
Products in accordance with the license scope set forth in Section 10.2.5.

          10.2.4  All licenses granted shall continue ***********************.

          10.2.5(a)  The licenses granted herein are licenses to (i) make,
have made, use, lease, offer for sale, sell and import Licensed Products; (ii)
make, have made, use and import machines, tools, materials and other
instruments, insofar as such machines, tools, materials and other instruments
are involved in or incidental to the development, manufacture, testing or repair
of Licensed Products which are or have been made, used, leased, owned, offered
for sale, sold or imported by the grantee of such license; and (iii) convey to
any customer of the grantee, with respect to any Licensed Product which is sold
or leased by such grantee to such customer, rights to use and resell such
Licensed Products as sold or leased by such grantee (whether or not as part of a
larger combination); provided, however, that no rights may be conveyed to
customers with respect to any invention which is directed to (1) a combination
of such Licensed Product (as sold or leased) with any other product, (2) a
method or process which is other than the inherent use of such Licensed Product
itself (as sold or leased), or (3) a method or process involving the use of a
Licensed Product to manufacture (including associated testing) any other
product.

          10.2.5(b)  Licenses granted herein are not to be construed either
(i) as consent by the grantor to any act which may be performed by the grantee,
except to the extent impacted by a patent licensed herein to the grantee, or
(ii) to include licenses to contributorily infringe or induce infringement under
U.S. law or a foreign equivalent thereof.

          10.2.5(c)  The grant of each license hereunder includes the right
to grant sublicenses within the scope of such license to a Party's Subsidiary
for so long as they remain a Subsidiary. Any such sublicense may be made
effective retroactively, but not prior to the Effective Date hereof, nor prior
to the sublicensees becoming a Subsidiary of such Party.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 20 -

<PAGE>   23
          10.2.5(d)  The right to have Licensed Products made pursuant to
this Joint Development Agreement is not limited to Licensed Products custom
designed by the grantee of the license, but shall include the right to have "off
the shelf" Licensed Products made for the grantee and its Subsidiary(ies).

          10.2.6  Lucent and Chartered shall be responsible for obtaining the
necessary signatures of their respective employees, agents or consultants,
including appropriate documents to effectuate assignment of ownership in such
Joint Invention. Lucent and Chartered shall also ensure that each of its
respective employees who is a co-inventor of any Joint Invention will devote
sufficient time to assist in the drafting and prosecution of the other Party's
assigned Joint Invention, so long as that employee continues to be employed by
that Party. If either Party is of the view that an employee of the other Party
is not devoting sufficient time to assist in the drafting or prosecution of its
assigned Joint Invention, then such matter shall be referred to the Steering
Committee for necessary action. Furthermore, each Party shall pay to its own
employees any patent/invention incentive that such Party would normally have
granted to its employees if the invention was solely invented by that Party. To
facilitate administration of each Party's respective patent/invention incentive
scheme, each Party shall provide to the other Party, with respect to each Joint
Invention assigned to the first mentioned Party, a monthly report indicating the
occurrence of any of the following dates in the lifetime of an assigned Joint
Invention:

     (a)  date that assigned Joint Invention was accepted for search/
          prosecution by that Party's patent committee;

     (b)  date of US filing of the assigned Joint Invention with the US PTO;
          and

     (c)  date of patent issuance by the US PTO.

          10.2.7  The Party that is the assigned owner of any and all resulting
patents arising from the Joint Invention, shall pay all filing, prosecution and
maintenance fees, and shall be entitled to all revenues derived by such Party
relating to the issued patent.

          10.2.8  If a Party chooses not to file any patent application for an
assigned Joint Invention, it may offer such Joint Invention to the other Party
for re-assignment. The Parties will make reasonable efforts to notify each other
about Joint Inventions that may be available for re-assignment, but failure to
provide such information will not constitute a breach of this Agreement. Upon
re-assignment of a Joint Invention to the other Party, Sections 10.2.3 through
10.2.7 would apply to such Joint Invention as if it had always been assigned to
the other Party.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 21 -

<PAGE>   24
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of  this document have been omitted and
                are filed separately with the Securities and Exchange Commission

     10.3  To avoid loss of patent rights as a result of premature public
disclosure of patentable information and in no way limiting Section 11
(Confidentiality), neither Party may publicly disclose or commercialize any
Joint Invention without the prior written consent of the other Party, unless (a)
a corresponding patent application has already been filed in any country where
such patent application will serve as the basis of establishing an effective
filing date for countries that are signatories to the Patent Cooperation Treaty,
or (b) ******************* have elapsed since the patentable information has
been considered by the Invention Disclosure Committee and the Party controlling
the Joint Invention has not declared in writing its intention to keep the Joint
Invention as a trade secret. Notwithstanding the foregoing, either Party may
commercialize a Joint Invention provided they are able to do so without
disclosing the trade secret or jeopardizing any patent rights.

     10.4  All patentable inventions and any intellectual property rights
therein which are created solely by Lucent's employees, agents or consultants
shall be solely owned by Lucent. All patentable inventions and any intellectual
property rights therein which are created solely by Chartered's employees,
agents or consultants shall be solely owned by Chartered.

11.0  CONFIDENTIALITY

     11.1  Subject to the provisions of Section 10.3, each Party shall keep
any technical information provided or disclosed by the other Party in confidence
or jointly developed by the Parties in confidence and shall not disclose such
information to any third party (except for customers, consultants, manufacturers
and contractors, as necessary to exercise any have made rights granted in this
Joint Development Agreement, which customers, consultants, manufacturers and
contractors have entered into a confidentiality agreement having terms
substantially similar to the confidentiality provisions contained in this Joint
Development Agreement) during the term of this Joint Development Agreement and
for a period of ************* thereafter.

     11.2  Each Party shall not disclose the terms and conditions of this
Joint Development Agreement to any third party, except to the EDB.

     11.3  The confidentiality obligations provided in Sections 11.1 and 11.2
shall not apply to any information which:

          11.3.1  is known by the receiving Party at the time of its receipt
thereof from the other Party;

          11.3.2  is publicly known through no fault of the receiving Party;

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 22 -
<PAGE>   25
          11.3.3  is rightfully provided to the receiving Party without any
restriction on disclosure by a third party;

          11.3.4  is independently developed by the receiving Party without use
of the information furnished by the disclosing Party;

          11.3.5  is required to be disclosed by laws or regulations of the
Republic of Singapore or the United States of America, as the case may be, or by
court order; provided, however, that the Party so required shall first have made
a good faith effort to obtain a protective order requiring that the information
and documents so disclosed be used only for the purposes for which the order was
issued; or

          11.3.6  is required to be disclosed by any securities commission,
exchange or securities regulatory or monitoring body (the "Regulators"), or to
provide or file any information with respect to this Joint Development Agreement
with the Regulators.

     11.4  Neither Party shall be liable for any inadvertent or accidental
disclosure of joint information or information received from the other Party
under this Joint Development Agreement, provided such disclosure occurs despite
the exercise of a reasonable degree of care which is at least as great as the
care such Party normally takes to preserve its own proprietary information of a
similar nature; and provided further, however, that the Party permitting any
material unauthorized disclosure shall use its best efforts to stop any material
unauthorized disclosure and to mitigate any damage caused thereby.

12.0  LIMITATION OF LIABILITY

     12.1  Each Party believes that the technical information to be furnished
by it hereunder will be true and accurate. However, neither Party shall be held
to any liability for errors or omissions in such technical information.

     12.2  Each Party warrants that the technical information and copyrights
licensed by such Party under this Joint Development Agreement are the original
work of such Party (or such Party has a valid right to license such property)
and it has the power to grant the rights described in this Joint Development
Agreement.

     12.3  Except as provided in Sections 12.1 and 12.2, the Parties make no
representations or warranties, expressly or impliedly. By way of example but not
of limitation, the Parties make no representations or warranties of
merchantability or fitness for any particular purpose with respect to any
technical information provided or licensed hereunder to any Party, or that the
use of any Party's

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 23 -
<PAGE>   26
technical information or any portion of it will not infringe any patent,
copyright, trademark or other intellectual property rights of any third party,
and it shall be the sole responsibility of the Party to make such determination
as is necessary with respect to the acquisition of licenses under patents or
other intellectual property rights of third Parties. The Parties shall not be
held to any liability with respect to any patent infringement of a patent owned
by a third party on account of, or arising from the use of any technical
information provided or licensed hereunder.

     12.4  NEITHER PARTY SHALL BE LIABLE FOR ANY INCIDENTAL, SPECIAL OR
CONSEQUENTIAL LOSS OR DAMAGE, INCLUDING LOST PROFITS OR LOST REVENUE ARISING OUT
OF THIS JOINT DEVELOPMENT AGREEMENT, WHETHER ARISING OUT OF BREACH OF WARRANTY,
BREACH OF CONTRACT, NEGLIGENCE, STRICT TORT LIABILITY OR OTHERWISE.

13.0  COMPLIANCE WITH RULES AND REGULATIONS AND INDEMNIFICATION

     13.1  Chartered's personnel shall, while on any location of Lucent in
connection with the joint development work under this Joint Development
Agreement, comply with Lucent's rules and regulations with regard to safety and
security. Lucent shall inform such personnel of such rules and regulations.
Chartered shall have full control over such personnel and shall be entirely
responsible for their complying with Lucent's rules and regulations. Chartered
agrees to indemnify and save Lucent harmless from any claims or demands,
including the costs, expenses and reasonable attorneys' fees incurred on account
thereof, that may be made by (i) anyone for injuries to persons or damage to
property to the extent they result from the willful misconduct or negligence of
Chartered's personnel; or (ii) Chartered's personnel based on Worker's
Compensation or any other similar laws or employment related claims to the
extent such claims are based on acts of Chartered. Chartered agrees to defend
Lucent, at Lucent's request, against any such claim or demand.

     13.2  Lucent's personnel shall, while on any location of Chartered, in
connection with the joint development work under this Joint Development
Agreement, comply with Chartered's rules and regulations with regard to safety
and security. Chartered shall inform such personnel of such rules and
regulations. Lucent shall have full control over such personnel and shall be
entirely responsible for their complying with Chartered's rules and regulations.
Lucent agrees to indemnify and save Chartered harmless from any claims or
demands, including the costs, expenses and reasonable attorneys' fees incurred
on account thereof, that may be made by (i) anyone for injuries to persons or
damage to property to the extent they result from the willful misconduct or
negligence of Lucent's personnel; or (ii) Lucent's personnel based on Worker's
Compensation or any other similar laws or employment related claims to the
extent such claims are based on acts of Lucent. Lucent agrees to defend
Chartered, at Chartered's request, against any such claim or demand.

     13.3  Lucent and Chartered shall, at all times, retain the administrative
supervision of their

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 24 -
<PAGE>   27

respective personnel.

14.0 TERM AND TERMINATION

     14.1  This Joint Development Agreement shall commence on the Effective
Date and shall expire upon the successful completion of the 0.08um Project,
as defined in Attachment E, at Chartered's Facility or Lucent's Facility or a
Chartered-Lucent joint venture facility, whichever is later.

     14.2  Termination For Breach

          14.2.1  If Chartered fails to fulfill one or more of its material
obligations under this Joint Development Agreement, Lucent may, upon its
election and in addition to any other remedies that it may have, at any time
terminate this Joint Development Agreement by not less than thirty (30) days
written notice to Chartered specifying any such breach, unless within the period
of such notice all breaches specified therein shall have been remedied to
Lucent's reasonable satisfaction. If the breach is not one which is capable of
being cured within thirty (30) days and Chartered has commenced to cure the
breach within such time and continues to do so diligently and in good faith,
then Chartered shall be granted an extension for a reasonable period of time.

          14.2.2  If Lucent fails to fulfill one or more of its material
obligations under this Joint Development Agreement, Chartered may, upon its
election and in addition to any other remedies that it may have, at any time
terminate this Joint Development Agreement by not less than thirty (30) days
written notice to Lucent specifying any such breach, unless within the period of
such notice all breaches specified therein shall have been remedied to
Chartered's reasonable satisfaction. If the breach is not one which is capable
of being cured within thirty (30) days and Lucent has commenced to cure the
breach within such time and continues to do so diligently and in good faith,
then Lucent shall be granted an extension for a reasonable period of time.

          14.2.3  Either Party may terminate this Joint Development Agreement
effective immediately by written notice if or when it is discovered that the
other Party has: (i) intentionally or in a willful, wanton or reckless manner,
made any material, false representation, report or claim relative hereto; (ii)
violated each other's copyright or trademark; (iii) become insolvent, invoked as
a debtor under any laws relating to the relief of debtors' or creditors' rights,
or has had such laws invoked against it; (iv) become involved in any liquidation
or termination of business; (v) been adjudicated bankrupt; or (vi) been involved
in an assignment for the benefit of its creditors.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 25 -
<PAGE>   28
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of  this document have been omitted and
                are filed separately with the Securities and Exchange Commission

          14.2.4  In the event of termination of this Joint Development
Agreement in accordance with this Section 14.2 due to breach by Lucent, Lucent
shall pay to Chartered the amount of the EDB RISC received by Chartered and
Lucent and required by the EDB to be reimbursed. In the event of termination of
this Joint Development Agreement in accordance with this Section 14.2 due to
breach by Chartered, Chartered shall pay to the EDB the amount of the EDB RISC
received by Chartered and Lucent and required by the EDB to be reimbursed.

          14.2.5  In the event Chartered terminates this Joint Development
Agreement for breach by Lucent, upon such termination Lucent agrees to forebear
in the use or licensing of any of the Chartered Background Information for a
period of ************ from the date of termination. In the event Lucent
terminates this Joint Development Agreement for breach by Chartered, upon such
termination Chartered agrees to forebear in the use or licensing of any of the
Lucent Background Information for a period of ************ from the date of
termination.

          14.2.6  In the event a Party terminates this Joint Development
Agreement for breach by the other Party, upon such termination the Party in
breach agrees to forebear in the use or licensing of any of the jointly owned
Foreground Information for a period of *********** from the date of termination.

     14.3  Termination For Convenience

          14.3.1  Either Party may terminate this Joint Development Agreement
for convenience by giving written notice at least ************* prior to the
planned successful completion of a Process (excluding Enhancement Modules) under
development, at Chartered's Facility or Lucent's Facility or a Chartered-Lucent
joint venture facility, whichever is later, and such termination shall be
effective upon the actual successful completion of that Process, as defined in
Attachment E.

          14.3.2  Upon termination of this Joint Development Agreement for
convenience in accordance with Section 14.3.1, neither Party shall be liable to
the other, either for compensation or for damages of any kind or character
whatsoever, whether on account of the loss by Lucent or Chartered of present or
prospective profits on sales or anticipated sales, or expenditures, investments
or commitments made in connection therewith, or on account of any other cause or
thing whatsoever. In the event of termination of this Joint Development
Agreement for convenience in accordance with Section 14.3.1, Lucent shall pay to
Chartered the amount of the EDB RISC received by Lucent and required by the EDB
to be reimbursed, and Chartered shall pay to the EDB the amount of the EDB RISC
received by Chartered and required by the EDB to be reimbursed.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 26 -

<PAGE>   29

     14.4  Upon expiration or termination of this Joint Development
Agreement, each Party shall immediately return all proprietary information
originated and owned solely by the other Party, except for that information
specifically needed for the support of the jointly developed Processes.

15.0  PUBLICITY AND TRADEMARKS AND TRADENAMES

     15.1  Each Party agrees to obtain prior written approval from the other
Party for any press release or public announcement referring to the other Party,
this Joint Development Agreement or to any of the terms and conditions herein.

     15.2  No right is granted herein to either Party to use any
identification (such as, but not limited to, trade names, trademarks, trade
devices, service marks or symbols, and abbreviations, contractions or
simulations thereof) owned by or used to identify the other Party or any of its
Subsidiaries or affiliates or any of its or their products, services or
organizations, and, with respect to the subject matter of this Joint Development
Agreement, each Party agrees that it will not, without the prior written
permission of the other Party, (i) use any such identification in advertising,
publicity, packaging, labeling or in any other manner to identify itself or any
of its products, services or organizations or (ii) represent directly or
indirectly that any product, service or organization of it is a product, service
or organization of the other Party or any of its Subsidiaries or affiliates, or
that any product or service of it is made in accordance with or utilizes any
information of the other Party or any of its Subsidiaries or affiliates.

16.0  NON-ASSIGNABILITY

Neither Party may assign this Joint Development Agreement nor the performance of
this Joint Development Agreement, or any part thereof, nor transfer licenses or
rights hereunder to anyone other than a Subsidiary without the written consent
of the other Party hereto. However, if either of the Parties divests all or a
portion of its business and such divested business continues operation as a
separately identifiable business, then the licenses granted hereunder to the
divesting Party may be assigned to such divested separate business, but only (i)
for the duration and term of licenses as specified in this Joint Development
Agreement, (ii) to the extent and for the time the divested business functions
as a separately identifiable business, and (iii) for products and services of
the kind provided by the divested business prior to its divestiture and not to
any products or services of any entity which acquires the divested business. Any
such divestiture or other business reorganization affecting the ownership or
title of any of a Party's patents shall be made subject to the rights and
obligations created under this Joint Development Agreement.

17.0  NOTICES

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 27 -
<PAGE>   30

All notices, demands, orders, acknowledgments or other communications required
or permitted under this Joint Development Agreement shall be in writing and
shall be deemed given: (i) when delivered personally; (ii) when sent by
facsimile; (iii) five (5) days after having been sent by registered or certified
mail, return receipt requested, postage prepaid; or (iv) three (3) days after
deposit with a commercial overnight carrier, with written verification of
receipt. All communications will be sent to the addresses set forth below.
Either Party may change its address by giving notice pursuant to this section.

     If sent to Lucent:

                         Lucent Technologies Inc.
                         Microelectronics Group
                         555 Union Boulevard
                         Allentown, PA 18103 USA

                         Attention: Mr. Glenn Schmehl
                         Title: Asset Management Director
                         Fax Number: 610-712-6223

     With a copy to:

                         Lucent Technologies Inc.
                         Microelectronics Law Group
                         Room 5SC03
                         Two Oak Way
                         Berkeley Heights, NJ 07922 USA

                         Attention: John W. Fisher
                         Fax Number: 908-508-8398

     If sent to Lucent Technologies Microelectronics:

                         Lucent Technologies Microelectronics Pte Ltd.
                         3 Kallang Sector
                         Kolam Ayer Industrial Park
                         Singapore 349278

                         Attention: Mr. Jeff Mowla
                         Title: Managing Director
                         Fax Number: 65-8402560

     If sent to Chartered:

                         Chartered Semiconductor Manufacturing Ltd.
                         60 Woodlands Industrial Park D Street 2

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 28 -
<PAGE>   31

                         Singapore 738406

                         Attention: Legal Department
                         Fax Number: 65-360-4970

18.0  AGREEMENT PREVAILS

This Joint Development Agreement shall prevail in the event of any conflicting
terms or legends which may appear on Lucent information or Chartered information
or any joint information.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 29 -

<PAGE>   32

19.0  NOTHING CONSTRUED

Neither the execution of this Joint Development Agreement nor anything in it or
in Lucent information or in Chartered information shall be construed as: (i) an
obligation upon either Party or their Subsidiaries to furnish, except as
provided in Section 3.4, any assistance of any kind whatsoever, or any products
or information other than Chartered information or Lucent information or to
revise, supplement or elaborate upon such information; or (ii) providing or
implying any arrangement or understanding that either Party or its Subsidiaries
will make any purchase from the other Party or its Subsidiaries; or (iii)
preventing either Party hereunder from pursuing other development activities
either alone or with another company.

20.0  FORCE MAJEURE

Neither Party shall be liable for any loss, damage, delay or failure of
performance resulting directly or indirectly from any cause which is beyond its
reasonable control, including but not limited to acts of God, riots, civil
disturbances, wars, states of belligerency or acts of the public enemy, strikes,
work stoppages, or the laws, regulations, acts or failure to act of any
governmental authority. In the event that performance under this Joint
Development Agreement is prevented for a continuous period of two (2) months or
longer by any of the foregoing causes, the Party not affected by the Force
Majeure events shall have the right to terminate this Joint Development
Agreement by giving written notice to the other Party. Upon termination of this
Joint Development Agreement in accordance with this Section 20.0, neither Party
shall be liable to the other, either for compensation or for damages of any kind
or character whatsoever, whether on account of the loss by Lucent or Chartered
of present or prospective profits on sales or anticipated sales, or
expenditures, investments or commitments made in connection therewith, or on
account of any other cause or thing whatsoever. In the event of termination of
this Joint Development Agreement for convenience in accordance with this Section
20.0, Lucent shall pay to Chartered the amount of the EDB RISC received by
Lucent and required by the EDB to be reimbursed, and Chartered shall pay to the
EDB the amount of the EDB RISC received by Chartered and required by the EDB to
be reimbursed.

21.0  CHOICE OF LAW

The Parties hereto desire and agree that the laws of the State of New York shall
apply in any dispute or controversy arising with respect to this Joint
Development Agreement, without regard to conflicts of laws provisions. The
United Nations Convention on Contracts for the International Sale of Goods shall
not apply to this Joint Development Agreement.

22.0  HEADINGS

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 30 -
<PAGE>   33
All section headings, including those in the Attachments are for convenience
purposes only and shall in no way affect, or be used, in the interpretation of
this Joint Development Agreement.

23.0  WAIVER

No failure, delay, relaxation or indulgence on the part of either Party in
exercising any power or right conferred upon such Party under the terms of this
Joint Development Agreement will operate as a waiver of such power or right nor
will any single or partial exercise of any such power or right preclude any
other or further exercise thereof or the exercise of any other power or right
under this Joint Development Agreement.

24.0  RELEASES VOID

Neither Party shall require waivers or releases of any personal rights from
representatives of the other in connection with visits to its premises and both
Parties agree that no such releases or waivers shall be pleaded by them or third
persons in any action or proceeding.

25.0  POWER TO SIGN

Chartered and Lucent covenant, warrant and represent that their respective
representatives signing this Joint Development Agreement have full power and
proper authority to sign this Joint Development Agreement and so bind the
Parties, and that there are no outstanding assignments, grants, licenses,
encumbrances, obligations or agreements, either written, oral or implied,
inconsistent with any provision of this Joint Development Agreement.

26.0  SURVIVAL OF OBLIGATIONS

The obligations of the Parties in Sections 1.0, 3.4, 9.0 through 32.0 of this
Joint Development Agreement shall survive termination or cancellation of this
Joint Development Agreement.

27.0  EXPORT CONTROL

The Parties acknowledge that the technical information (including, but not
limited to, services and training) provided under this Joint Development
Agreement are subject to U.S. export laws and regulations and any use or
transfer of such technical information must be authorized under those laws and
regulations. The Parties agree that they will not use, distribute, transfer, or
transmit the technical information (even if incorporated into products) except
in compliance with U.S. export regulations. If necessary, Lucent may request
Chartered to sign written assurances and other export-related documents as may
be required for Lucent to comply with U.S. export regulations.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 31 -
<PAGE>   34

28.0  DISPUTE RESOLUTION

     28.1  If a dispute arises out of or relates to this Joint Development
Agreement, or the breach, termination or validity thereof, the Parties agree to
submit the dispute to a sole mediator selected by the Parties or, at any time at
the option of a Party, to mediation by the International Chamber of Commerce
("ICC"). If not thus resolved, it shall be referred to a sole arbitrator
selected by the Parties within thirty (30) days of the mediation, or in the
absence of such selection, to ICC arbitration which shall be governed by the
United States Arbitration Act.

     28.2  Any award made: (i) shall be a bare award limited to a holding for
or against a Party and affording such remedy as is deemed equitable, just and
within the scope of this Joint Development Agreement; (ii) shall be without
findings as to issues (including but not limited to patent validity and/or
infringement) or a statement of the reasoning on which the award rests; (iii)
may in appropriate circumstances (other than patent disputes) include injunctive
relief; (iv) shall be made within four (4) months of the appointment of the
arbitrator; and (v) may be entered in any court of competent jurisdiction.

     28.3  The requirement for mediation and arbitration shall not be deemed
a waiver of any right of termination under this Joint Development Agreement and
the arbitrator is not empowered to act or make any award other than based solely
on the rights and obligations of the Parties prior to any such termination.

     28.4  The arbitrator shall be knowledgeable in the legal and technical
aspects of this Joint Development Agreement and shall determine issues of
arbitrability but may not limit, expand or otherwise modify the terms of this
Joint Development Agreement.

     28.5  The place of mediation and arbitration shall be New York City.

     28.6  Each Party shall bear its own expenses but those related to the
compensation and expenses of the mediator and arbitrator shall be borne equally.

     28.7  A request by a Party to a court for interim measures shall not be
deemed a waiver of the obligation to mediate and arbitrate.

     28.8  The arbitrator shall not have authority to award punitive or other
damages in excess of compensatory damages and each Party irrevocably waives any
claim thereto.

     28.9  The Parties, their representatives, other participants and the
mediator and arbitrator shall hold the existence, content and result of
mediation and arbitration in confidence.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 32 -
<PAGE>   35

29.0  PARTIAL INVALIDITY

If any paragraph, provision, or section thereof in this Joint Development
Agreement shall be found or be held to be invalid or unenforceable in any
jurisdiction in which this Joint Development Agreement is being performed, the
remainder of this Joint Development Agreement shall be valid and enforceable and
the Parties shall negotiate, in good faith, a substitute, valid and enforceable
provision which most nearly effects the Parties' intent in entering into this
Joint Development Agreement.

30.0  COUNTERPARTS

This Joint Development Agreement may be executed in two or more counterparts,
all of which, taken together, shall be regarded as one and the same instrument.

31.0  RELATIONSHIP OF PARTIES

The Parties to this Joint Development Agreement are independent contractors.
There is no relationship of agency, partnership, joint venture, employment or
franchise between the Parties with respect to the subject matter of this
Agreement. Neither Party has the authority to bind the other or to incur any
obligation on its behalf.

32.0  INTEGRATION

This Joint Development Agreement sets forth the entire agreement and
understanding between the Parties as to the subject matter hereof and merges all
prior discussions and agreements between them. Neither of the Parties shall be
bound by any warranties, modifications, understandings or representations with
respect to the subject matter hereof other than as expressly provided herein, or
in a writing signed with or subsequent to the execution hereof by an authorized
representative of the Party to be bound thereby.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 33 -

<PAGE>   36

IN WITNESS WHEREOF the Parties hereunto have entered into this Joint Development
Agreement as of the Effective Date.

CHARTERED SEMICONDUCTOR MANUFACTURING LTD.

By: /s/ Barry Waite
   ----------------------------------------
Name:  Barry Waite
Title: President & Chief Executive Officer
Date:  August 10, 2000

LUCENT TECHNOLOGIES INC.

By: /s/ John T. Dickson
   ----------------------------------------
Name:  John T. Dickson
Title: Executive Vice President and Chief Executive Officer,
       Microelectronics & Communications Technologies
Date:  August 10, 2000

LUCENT TECHNOLOGIES MICROELECTRONICS PTE LTD.

By: /s/ Jeff Mowla
   ----------------------------------------
Name:  Jeff Mowla
Title: Managing Director
Date:  August 10, 2000

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 34 -
<PAGE>   37
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of  this document have been omitted and
                are filed separately with the Securities and Exchange Commission

                                  ATTACHMENT A

                                DEVELOPMENT PLANS

Note: The initial 0.12um Development Plan is attached as Attachment A-1-1.
Any revised Development Plan shall supercede the earlier applicable Attachment,
and shall be attached to this Joint Development Agreement and successively
numbered. For example, revised 0.12um Development Plan(s) will be named
"Attachment A-1-2", "Attachment A-1-3", etc. The 0.10um Development Plan(s)
will be named as "Attachment A-2-1", "Attachment A-2-2", "Attachment A-2-3",
etc. The 0.08um Development Plan(s) will be named as "Attachment A-3-1",
"Attachment A-3-2", "Attachment A-3-3", etc.

These technologies are defined principally by the design rules, and the
transistor options, with associated electrical characteristics. Corresponding
documentation and specification are defined in the list of foreground
deliverables, applicable to all three generations.

The development plan for each core ***** technology node (0.12um, 0.10um
and 0.08um) is outlined by the High Level Milestones and Foreground
Deliverables. The qualification of the *** ************** modules is expected to
be completed concurrent with the core ******. The qualification of the ****
module is expected to be completed within five (5) months of the core *****. The
******** module will be completed on a mutually agreed date.

The same elements will be defined for 0.10um and 0.08um technologies as
soon as practical (e.g., 0.10um by 1Q01 and 0.08um by 1Q02). These
defining elements will be approved by the Steering and Executive Committees, and
then attached to this document.

The Parties will in good faith negotiate and agree to a detailed workplan for
the joint development of each Process (the "Workplan"). The Workplan shall be a
detailed elaboration of the Development Plan and shall be approved and signed
off by the Executive Committee not later than the date of execution of this
Joint Development Agreement. All subsequent amendments to the Workplan shall be
approved by the Executive Committee.

Minimum monthly manpower commitment by both Parties to the Development Plan is
defined in the Manpower Plan.

Development of Processes is deemed successful and complete when all deliverables
defined in Attachment E are attained.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 35 -
<PAGE>   38
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of this document have been omitted and
                are filed separately with the Securities and Exchange Commission

MANPOWER PLAN
(Headcount)

                                    * * * * *

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 36 -

<PAGE>   39
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of this document have been omitted and
                are filed separately with the Securities and Exchange Commission

                                ATTACHMENT A-1-1

                          (0.12um DEVELOPMENT PLAN)

For the 0.12um CMOS technology, the high level design rules, transistor
options, milestones, and foreground deliverables follows:

DESIGN RULES

                                    * * * * *

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 37 -
<PAGE>   40

REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of this document have been omitted and
                are filed separately with the Securities and Exchange Commission

0.12um TRANSISTOR OPTIONS

--------------------------------------------------------------------------------

                                     *******

--------------------------------------------------------------------------------

0.12um HIGH LEVEL PROGRAM MILESTONES

--------------------------------------------------------------------------------
            Milestone                                   Date
--------------------------------------------------------------------------------
             * * * *                                   * * * *
--------------------------------------------------------------------------------

FOREGROUND DELIVERABLES

The following are the deliverables necessary to complete the Development Plan.
The date and responsibility for delivery of each such deliverable must be
determined by mutual agreement of the Parties and will be reflected in the
Workplan.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 38 -
<PAGE>   41

REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of this document have been omitted and
                are filed separately with the Securities and Exchange Commission

--------------------------------------------------------------------------------
1.  TECHNOLOGY
--------------------------------------------------------------------------------
    1.1.  ELECTRICAL (EP) SPECIFICATION AND TEST PROGRAM
--------------------------------------------------------------------------------

                                    * * * * *

--------------------------------------------------------------------------------
    1.2.  SCRIBELINE TEST STRUCTURES
--------------------------------------------------------------------------------

                                    * * * * *

--------------------------------------------------------------------------------
    3.3.  DESIGN RULES AND MODELS
--------------------------------------------------------------------------------

                                    * * * * *

--------------------------------------------------------------------------------

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 39 -
<PAGE>   42

REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of this document have been omitted and
                are filed separately with the Securities and Exchange Commission

--------------------------------------------------------------------------------
    1.4.  RUNFLOW AND RECIPE SPEC AND PROCESS CHARACTERIZATION REPORTS
--------------------------------------------------------------------------------

                                   * * * * *

--------------------------------------------------------------------------------
    1.5.  EQUIPMENT SPECIFICATION
--------------------------------------------------------------------------------

                                   * * * * *

--------------------------------------------------------------------------------
    1.6.  QUALIFICATION PLAN AND VEHICLE
--------------------------------------------------------------------------------

                                    * * * * *

--------------------------------------------------------------------------------
2.  DEFECT DENSITY
--------------------------------------------------------------------------------
    2.1.  TOOLING (MASK) METHODOLOGY
--------------------------------------------------------------------------------

                                    * * * * *

--------------------------------------------------------------------------------
    2.2.  YIELD ENHANCEMENT PROGRAM
--------------------------------------------------------------------------------

                                    * * * * *

--------------------------------------------------------------------------------

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 40 -
<PAGE>   43

REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of this document have been omitted and
                are filed separately with the Securities and Exchange Commission

--------------------------------------------------------------------------------
3.  PROGRAM MANAGEMENT
--------------------------------------------------------------------------------
    3.1.  RESOURCE PROVISIONS AND MILESTONES
--------------------------------------------------------------------------------

                                    * * * * *

--------------------------------------------------------------------------------
4.  EDA
--------------------------------------------------------------------------------
    4.1.  DEVICE CHARACTERIZATION AND LAYOUT
--------------------------------------------------------------------------------

                                    * * * * *

--------------------------------------------------------------------------------

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 41 -
<PAGE>   44

                                ATTACHMENT A-2-1

                          (0.10um DEVELOPMENT PLAN)

To be attached following approval of Executive Committee.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 42 -
<PAGE>   45

                                ATTACHMENT A-3-1

                          (0.08um DEVELOPMENT PLAN)

To be attached following approval of Executive Committee.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 43 -
<PAGE>   46

                                  ATTACHMENT B

                               TOTAL PROJECT COST

Please refer to the attached 2 pages.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 44 -

<PAGE>   47
ATTACHMENT B-1-1.1
TOTAL PROJECT COST

Technology:
Site:             0.12um Process Technology          with 0.08um development
Budget Periods:

ESTIMATE FOR COST OF DEVELOPMENT (US$)
<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------------
                                                     CHARTERED TRANSFER/S'PORE
-----------------------------------------------------------------------------------------------------------------------------------
                                                                1999      2000      2001      2002      2003      2004       Total-
                                        Units     Unit Cost                                                       -----------------
-----------------------------------------------------------------------------------------------------------------------------------
<S>                                     <C>       <C>           <C>       <C>       <C>      <C>       <C>       <C>        <C>
MANPOWER
Chartered -- Salary
Lucent -- Salary
Singapore Bell Labs
Overseas Allow.
Lodging costs
Transportation
Air fare

MATERIALS
Controlled Wafers
Processed wafers* 0.12um
Processed wafers* 0.10um
Processed wafers* 0.08um
Consumables
Reticles (0.12um + 0.10um)
Reticles (0.08um)
-------------------------------
-------------------------------

MISCELLANEOUS
Failure analysis
Packaging, Burn-in
JDP with design houses/req inst
Offices, supplies, etc.
Moves & installations
-------------------------------
Sub-total expenses
-------------------------------

CAPEX
Equipment
Installation costs
-------------------------------
Total Project Funding
-------------------------------
<CAPTION>
-----------------------------------------------------------------------------------------------------------------------------------
                                                     JOINT DEVELOPMENT IN ORLANDO
-----------------------------------------------------------------------------------------------------------------------------------
                                                               1999     2000     2001     2002    2003    2004     Total-     Grand
                                       Units    Unit Cost                                                 ---------------     Total
-----------------------------------------------------------------------------------------------------------------------------------
<S>                                     <C>       <C>           <C>       <C>       <C>      <C>       <C>       <C>        <C>
MANPOWER
Chartered -- Salary
Lucent -- Salary
Singapore Bell Labs
Overseas Allow.
Lodging costs
Transportation
Air fare

MATERIALS
Controlled Wafers
Processed wafers* 0.12um
Processed wafers* 0.10um
Processed wafers* 0.08um
Consumables
Reticles (0.12um + 0.10um)
Reticles (0.08um)
-------------------------------
-------------------------------

MISCELLANEOUS
Failure analysis
Packaging, Burn-in
JDP with design houses/req inst
Offices, supplies, etc.
Moves & installations
-------------------------------
Sub-total expenses
-------------------------------

CAPEX
Equipment
Installation costs
-------------------------------
Total Project Funding
-------------------------------
</TABLE>
<PAGE>   48
ATTACHMENT B-1-1.2
TOTAL PROJECT COST - MANPOWER AND WAFERS

Technology           0.12um Process Technology - 0.08um development

<TABLE>
<CAPTION>
Headcount
                                          4Q99    1Q00    2Q00    3Q00    4Q00    1Q01    2Q01    3Q01    4Q01    1Q02    2Q02
<S>                                       <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
------------------------------------
------------------------------------
------------------------------------
------------------------------------

Wafers
------------------------------------
------------------------------------
------------------------------------
------------------------------------
------------------------------------
------------------------------------
------------------------------------
------------------------------------
------------------------------------

Inflation factor
Manpower salary
CHRT                                                                            * * * * *

Manpower salary
CHRT @ Lucent

Manpower salary
Lucent@ Lucent

Manpower salary
Singapore Bell Labs

<CAPTION>

Headcount                                                                                                                 Total Man-
                                          3Q02    4Q02    1Q03    2Q03    3Q03    4Q03    1Q04    2Q04    3Q04    4Q04     Mth/Wfr
<S>                                       <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>     <C>
------------------------------------
------------------------------------
------------------------------------
------------------------------------

Wafers
------------------------------------
------------------------------------
------------------------------------
------------------------------------
------------------------------------
------------------------------------
------------------------------------
------------------------------------
------------------------------------

Inflation factor
Manpower salary
CHRT                                                                            * * * * *

Manpower salary
CHRT @ Lucent

Manpower salary
Lucent@ Lucent

Manpower salary
Singapore Bell Labs

</TABLE>
<PAGE>   49
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of this document have been omitted and
                are filed separately with the Securities and Exchange Commission

                                  ATTACHMENT C

                        SINGAPORE BELL LABORATORIES STAFF

1.  Lucent will be responsible for:

         (a)  employment of at least forty (40) Bell Laboratories staff, through
    its Singapore subsidiary Lucent Technologies Microelectronics Pte Ltd and
    attaching the same to Singapore Bell Laboratories by **************. The
    hiring plan shall be in accordance with the Total Project Cost set out in
    Attachment B.

         (b)  all costs and expenses related to the employment of the forty (40)
    Bell Laboratories staff, including salary, taxes, employment passes (if the
    Bell Laboratories staff are not Singaporean or Singapore Permanent
    Residents), housing, allowances and transport (including airfare).

2.  Chartered will be responsible for:

         (a)  providing Singapore Bell Laboratories staff with work space in
    Chartered's Facility;

         (b)  providing Singapore Bell Laboratories staff with access to
    Chartered's Facility;

         (c)  attaching at least forty (40) Chartered engineers to Singapore
    Bell Laboratories by *************. The hiring plan shall be in accordance
    with the Total Project Cost set out in Attachment B.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 45 -
<PAGE>   50

                                  ATTACHMENT D

                    INFORMATION FOR RELEASE TO THIRD PARTIES

1.  Design Information-Per Design Manual

    1.1.  Design Rules (including reliability layout rules)

    1.2.  Layout Description

    1.3.  ESD, Latch-up, Pad Rules

    1.4.  DRC, ERC, LVS, LPE

2.  Electrical Targets Information-Per Design Manual

    2.1.  RAM Cell Transistor

    2.2.  MOS Transistors

    2.3.  Other Devices (Bipolar Devices, Diode, Resistor, Capacitor)

    2.4.  Parasitic Resistor and Capacitor

    2.5.  SPICE Models and Device Characterization reports

    2.6.  Interconnect Delay Models

3.  Process Information-Per Design Manual

    3.1.  Simple Process Flow

    3.2.  Electrical Test Specification

    3.3.  Qualification report

4.  Mask Generation-Per Specific Mask Generation Information

    4.1.  Mask Specification

    4.2.  Bias Table

    4.3.  Mask Layer Generation Equation-Per Design Manual

    4.4.  Tooling Methodologies like Dummy Pattern Algorithm, OPC and phase
          shift procedures

5.  Information for Test and Sort Capability

    5.1.  Transfer vehicle Program files

          5.1.1.  Main program file for pre DS

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 46 -
<PAGE>   51

          5.1.2.  Socket file

          5.1.3.  All micro pattern files

          5.1.4.  Insert to pattern file (SDEF File)

          5.1.5.  Probe area file

          5.1.6.  Scramble file

    5.2.  Device Test and Design Documentation

          5.2.1.  Wafer Test Spec

          5.2.2.  Wafer Test Pattern Description

          5.2.3.  Wafer Test Timing Diagram

          5.2.4.  Wafer Test Flow

          5.2.5.  Test Commands Description

          5.2.6.  IPL mode description

    5.3.  Probe card document

          5.3.1.  Pads size

          5.3.2.  Pad to Pad pitch size

          5.3.3.  Pad x, y coordinates table

    5.4.  Final Test

          5.4.1.  Final Test program

          5.4.2.  Final Test Spec

          5.4.3.  Product Test Flow

          5.4.4.  Test board pin connection

          5.4.5.  Test board load circuit

          5.4.6.  Device data Sheet

          5.4.7.  Bonding diagram

    5.5.  Burn-In Test

          5.5.1.  Product level Burn-In criteria

          5.5.2.  Burn-In mode Sequence

          5.5.3.  Burn-In Cycle

          5.5.4.  Burn-In Testing Waveform

          5.5.5.  Burn-In Board Waveform

          5.5.6.  HIFIX wiring, socket file, tray drawing

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 47 -
<PAGE>   52
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of this document have been omitted and
                are filed separately with the Securities and Exchange Commission

                                  ATTACHMENT E

     COMPLETION OF PROJECT FOR 0.12um, 0.10um AND 0.08um PROCESSES

A Process is deemed to be successfully completed when a receiving facility's
qualification achieves the following:

     (a)  the electrical and physical specifications of such Process achieved
at the receiving facility match the electrical and physical specifications of
such Process achieved in the development facility, and

     (b)  the reliability performance of such Process at the receiving facility
is the same as or better than the reliability performance of such Process
achieved in the development facility. The reliability requirement at the
development facility shall be

                                    * * * * *

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 48 -
<PAGE>   53

REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of this document have been omitted and
                are filed separately with the Securities and Exchange Commission

                                  ATTACHMENT F

        PROCEDURE FOR JOINT SELECTION OF TOOL SET AND MATERIALS FOR JOINT
                          DEVELOPMENT OF THE PROCESSES

1.0  PURPOSE

This Attachment F describes the procedure for review and final approval by the
Executive Committee of new toolset and materials purchased or evaluated under
the Joint Development Agreement. Under this procedure Chartered and Lucent will
establish joint tool and materials selection teams for the purpose of
identifying toolset and materials for maximum manufacturing efficiency and
lowest cost of ownership of the jointly developed Processes. Process
extendibility to cover the 0.12, 0.10 and 0.08 um Processes will also be a
key factor in the selection criteria. ******************************************
*******************************************************************************.

2.0  SCOPE

This Attachment F applies to all new processing tools and materials, including
metrology tools, purchased or evaluated by either Party for the purpose of
development and eventual manufacturing of the jointly developed Processes. Tool
evaluations performed as part of a joint development agreement with a supplier
are covered under this procedure.

3.0  DEFINITION

<TABLE>
<S>             <C>             <C>
3.1             TOC             Tool of choice
3.2             MOC             Material of choice
3.3             JDP             Joint development program
3.4             EST             Equipment/tool selection team
3.5             CST             Commodities selection team
3.6             SC              Steering Committee
3.7             EC              Executive Committee
3.8             COO             Cost of ownership
</TABLE>

4.0  REFERENCE DOCUMENTS

                                    * * * * *

                          CHARTERED-LUCENT CONFIDENTIAL

                                     - 49 -
<PAGE>   54

5.0  RESPONSIBILITIES

REQUESTOR (LUCENT OR CHARTERED):

[ ]  The requestor shall inform the SC of any potential tool/material for
     purchase or evaluation.

[ ]  The requestor shall provide all the necessary data such as acceptance
     criteria, COO etc. to enable the EST/CST to make a tool/material
     recommendation to the SC.

[ ]  The requestor is responsible for the execution of tool and materials
     evaluations and reporting of results back to the joint EST/ CST.

LUCENT:

[ ]  Lucent is to engage Chartered in any JDP agreements with suppliers
     on potential tools and materials that may affect the Chartered or Lucent
     TOC/MOC to be used in jointly developed Processes.

[ ]  Lucent shall inform Chartered of any changes to their TOC/MOC.

CHARTERED:

[ ]  Chartered is to engage Lucent in any JDP agreements with suppliers on
     potential tools and materials that may affect the Chartered or Lucent
     TOC/MOC to be used in jointly developed Processes.

[ ]  Chartered shall inform Lucent of any changes to their TOC/MOC.

EST:

[ ]  The EST leads the selection process for the proposed tool and delivers a
     recommendation to the SC.

CST:

[ ]  The CST leads the selection process for the proposed materials and delivers
     a recommendation to the SC.

SC:

[ ]  The SC shall nominate the EST/CST team leader for the purpose of
     coordinating and reporting to the SC on the progress and conclusions of the
     joint tool/material selection activities.

[ ]  The SC shall make a recommendation based on the output of the EST/CST
     activity to the EC.

EC:

[ ]  The EC has the authority for final approval of tools and materials for
     joint development of the Processes.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 50 -
<PAGE>   55
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of this document have been omitted and
                are filed separately with the Securities and Exchange Commission

6.0  PROCEDURES

The EST and CST teams are formed under direction and guidance of the SC to
select tools and materials for development and eventual manufacturing of the
jointly developed Processes. The composition of the teams is described below and
may be varied subject to the approval and recommendations of the SC.

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------
ORGANIZATION/ DEPARTMENT REPRESENTED           EST                  CST
--------------------------------------------------------------------------------
<S>                                            <C>                  <C>

                                    * * * * *

--------------------------------------------------------------------------------
</TABLE>

6.1  EST CRITERIA FOR TOOL AND MATERIALS SELECTION

Attached below is a summary of the selection criteria to be used by the EST for
the purpose of joint tool selection. Further details of the procedures and
decision analysis can be found in *** **. Weightages attached to each of the
selection criteria may vary in accordance with the EST team recommendation and
is subject to the approval of the SC.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 51 -
<PAGE>   56
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of this document have been omitted and
                are filed separately with the Securities and Exchange Commission

<TABLE>
<CAPTION>
-----------------------------------------------------------------------------------------------
REQUESTER'S INPUT SOURCE       CRITERIA             WEIGHTAGE             VENDOR A         TOC
                                                   (see note 1)
-----------------------------------------------------------------------------------------------
<S>                            <C>                 <C>                    <C>              <C>

                                   * * * * *

-----------------------------------------------------------------------------------------------
</TABLE>

Note 1.

WEIGHTAGES MAY VARY IN ACCORDANCE WITH THE EST TEAM RECOMMENDATION AND ARE
SUBJECT TO THE APPROVAL OF THE SC.

There are 4 parts to the procedures for purchase and/or evaluation of new tools
and materials:

<TABLE>
<S>               <C>

PART A:           COMPATIBILITY OF THE PROPOSED TOOL/MATERIAL TO THE CURRENT CHARTERED OR LUCENT TOC/ MOC.
PART B:           EST AND CST PROPOSAL TO SC
PART C:           TOOL/MATERIAL EVALUATION PHASE
PART D:           SC FINAL REVIEW
</TABLE>

The accompanying flowchart summarizes the process flow and descriptions of each
of the procedures (parts A to D) are subsequently provided in Sections 6.2 and
6.3.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 52 -
<PAGE>   57
               [GRAPHICAL CHART DESCRIBING THE PROCEDURE FOR THE
              EVALUATION AND PURCHASE OF NEW TOOLS AND MATERIALS]

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 53 -
<PAGE>   58
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of this document have been omitted and
                are filed separately with the Securities and Exchange Commission

6.2  PROCEDURE FOR PROPOSED TOOL EVALUATION AND PURCHASE

                                    * * * * *

PART A:  COMPATIBILITY OF THE PROPOSED TOOL TO THE CURRENT TOC

     6.2.1   If the proposed tool is not listed in the TOC list in Table F(i),
             an appropriate joint EST will be formed in order to evaluate and
             make recommendations to the SC.

     6.2.2   If the proposed tool is listed in the TOC list in table F(i), then
             the proposal goes directly to the SC and EC for recommendation to
             purchase or lease.

     6.2.3   The SC shall be notified of any changes to the Chartered or Lucent
             TOC as given in Table F (i) by the EST.

PART B:  EQUIPMENT SELECTION TEAM PROPOSAL TO SC

     6.2.4   A joint EST will be formed comprising team members from Lucent and
             Chartered as described in section 6.0 of this Attachment.

     6.2.5   The SC will appoint an EST team leader to co-ordinate and report on
             the activities of the EST.

     6.2.6   The Chartered or Lucent requestor is to provide all the available
             tool acceptance data as inputs to the EST selection process.

     6.2.7   The proposed tool will be given the same weightage in comparison to
             the other tools during the selection process.

     6.2.8   The EST is to perform a side-by-side tool comparison based on the
             data supplied by Lucent as well as Chartered.

     6.2.9   The EST is to make a recommendation to the SC.

     6.2.10  If approval is not granted, the SC issues a written notice stating
             the reason for rejection.

     6.2.11  If approval is granted, the EST can proceed to parts C or D as
             described below.

                          CHARTERED-LUCENT CONFIDENTIAL

                                     - 54 -
<PAGE>   59
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of this document have been omitted and
                are filed separately with the Securities and Exchange Commission

PART C:  TOOL EVALUATION PHASE

     6.2.12  The EST is to select the site of evaluation and coordinate the
             on-site evaluation task force for the proposed tool.

     6.2.13  The EST is to set the timeline to verify the Process acceptance
             criteria as stipulated by the requestor for the new tool in
             question as well as the hardware reliability.

     6.2.14  EST makes a final recommendation to the SC based on the on-site
             evaluation.

PART D:  STEERING COMMITTEE FINAL REVIEW

     6.2.15  The SC reviews the final recommendation from the EST or a request
             to purchase a TOC as listed in Table F(i).

     6.2.16  If the SC does not accept the recommendation of the EST, the SC
             issues a written notice stating the reason for rejection.

     6.2.17  If the SC accepts the recommendation of the EST, the SC makes a
             proposal to the EC to update the TOC.

     6.2.18  In the case of a request to purchase a TOC,) and the Parties have a
             different TOC listed in Table F(i), the SC may recommend a joint
             EST be formed to execute phases B and C above so that a convergent
             TOC can be identified.

     6.2.19  The decision of the SC to purchase or lease tools is subject to the
             final approval of the EC.

6.3  PROCEDURES FOR NEW MATERIAL EVALUATION AND PURCHASE

                                    * * * * *

PART A:  COMPATIBILITY OF THE PROPOSED MATERIAL TO THE CURRENT MOC

     6.3.1   If the proposed material is not listed in the MOC list in
             Table F(ii), an appropriate joint CST will be formed in order to
             evaluate and make recommendations to the SC.

     6.3.2   If the proposed material is listed in the MOC list in Table F(ii),
             then the proposal goes

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 55 -
<PAGE>   60

     6.3.3   straight to the SC and EC for recommendation to purchase.

     6.3.4   The SC shall be notified of any changes to the Chartered or Lucent
             MOC as given in Table F (ii) by the CST.

PART B:  COMMODITIES SELECTION TEAM PROPOSAL TO SC

     6.3.4   A joint CST will be formed comprising team members from Lucent and
             Chartered as described in section 6.0 of this Attachment.

     6.3.5   The SC will appoint a CST team leader to co-ordinate and report on
             the activities of the CST.

     6.3.6   The Chartered or Lucent requestor is to provide all the available
             material acceptance data as inputs to the CST selection process.

     6.3.7   The proposed material will be given the same weightage in
             comparison to the other materials during the selection process.

     6.3.8   The CST is to perform a side-by-side material comparison based on
             the data supplied by Lucent as well as Chartered.

     6.3.9   The CST is to make a recommendation to the SC.

     6.3.10  If the approval is not granted, SC issues a written notice stating
             the reason for rejection.

     6.3.11  If approval is granted, the CST can proceed to parts C or D as
             described below.

PART C:  MATERIAL EVALUATION PHASE

     6.3.12  The CST is to select the site for evaluation and to coordinate the
             on-site evaluation task force for the proposed new material.

     6.3.13  The CST is to set the timeline to verify the Process acceptance
             criteria as stipulated by the requestor for the new material.

     6.3.14  CST makes a final recommendation to the SC based on the on-site
             evaluation.

                          CHARTERED-LUCENT CONFIDENTIAL

                                     - 56 -
<PAGE>   61

PART D:  STEERING COMMITTEE FINAL REVIEW

     6.3.15  The SC reviews the final recommendation from the CST.

     6.3.16  If the SC does not accept the recommendation of the CST, the SC
             issues a written notice stating the reason for rejection.

     6.3.17  If the SC accepts the recommendation of the CST, the SC makes a
             proposal to the EC to update the MOC.

     6.3.18  The SC may recommend an appropriate CST be formed for the purpose
             of identifying a convergent MOC if the Parties MOC, as listed in
             Table F(ii), is different.

     6.3.19  The decision of the SC to purchase materials is subject to the
             final approval of the EC.

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 57 -
<PAGE>   62
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of this document have been omitted and
                are filed separately with the Securities and Exchange Commission

                                TABLE F(I) (TOC)

--------------------------------------------------------------------------------

                                    * * * * *

--------------------------------------------------------------------------------

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 58 -
<PAGE>   63
REDACTED        CONFIDENTIAL TREATMENT REQUESTED
                The asterisked portions of this document have been omitted and
                are filed separately with the Securities and Exchange Commission

                               TABLE F(II) (MOC)

--------------------------------------------------------------------------------

                                   * * * * *

--------------------------------------------------------------------------------

                         CHARTERED-LUCENT CONFIDENTIAL

                                     - 59 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}]]